

PARTNERSHIP • INNOVATION • EDUCATION • COLLABORATION

2008

Final Program



Sheraton Centre Toronto • November 30 - December 3, 2008

8TH Canadian Immunization CONFERENCE

Hosted by:



Public Health Agency of Canada

Agence de la santé publique du Canada

In collaboration with:



CONFERENCE SUPPORTERS



The Organizing Committee of the 8th Canadian Immunization Conference gratefully acknowledges the following companies for their generous contribution toward the success of the Conference and their continued commitment to the immunization and vaccine health community.

Platinum



sanofi pasteur

The vaccines division of sanofi-aventis Group



Wyeth®

Silver



Dear Colleagues, Invited Guests and Participants:

On behalf of the Organizing Committee, we are very pleased to welcome you to the vibrant city of Toronto for the 8th Edition of the Canadian Immunization Conference!

This year's program will highlight the power of Partnership, Innovation and Education. The Program Committee used an innovative approach in the development of the scientific program. To facilitate as much active participation as possible from the conference's varied audiences, a cross section of workers from all spheres of the immunization field was involved in the selection of the learning tracks and development of the program. The result is a comprehensive program offering 15 additional concurrent sessions! The multiple workshops and featured sessions will cover the full spectrum of immunization from new developments in vaccinology science, to the implementation and evaluation of immunization programs, education and training as well and global immunization efforts.

In keeping with the Conference theme, the scientific program will introduce new *Immunization Competencies for Health Professionals* developed to support safe and competent practices in immunization and to ensure high immunization coverage rates in the community. These competencies are woven into the final program using identifiers which guide participants as to the competencies being addressed in each session. We invite you to keep track of your learning using the table found at the end of this program.

As an integral part of the program, we will once again enjoy a display of posters drawn by Grade 6 students for the Canadian Immunization Poster Contest coordinated by the Canadian Coalition for Immunization Awareness & Promotion. Prizes for the contest were kindly donated by BioteCANADA and Owl Kids Magazine. The contest and materials were designed to educate grade 6 students about the importance of immunization.

We would like to take this opportunity to thank our collaborators, the members of the Program and Operational Committees as well as sub-committees, session chairpersons, and Public Health Agency staff for their dedication and hard work on this conference. We would also like to thank our generous supporters whose donations have made this Conference possible.

We invite you to enjoy the exciting city of Toronto as we increase our knowledge and strengthen our commitment to immunization in Canada.

Co-chairs




Arlene King
Public Health Agency of Canada




Debra Lynkowski
Canadian Public Health Association



Dear Conference Participants,

On behalf of the Public Health Agency, it is my pleasure to welcome you to the 8th Canadian Immunization Conference in Toronto. I want to acknowledge our collaborators in hosting this conference, the Canadian Paediatric Society, the Canadian Public Health Association, and the Canadian Association for Immunization Research and Evaluation, as well as our Organizing Committee, for their dedication in making this conference a reality. I would also like to recognize the financial support from the private sector.

This bi-annual conference aims to strengthen our evidence-based immunization programs in Canada and presents those in the immunization field with an opportunity to share best practices, present new ideas, and engage in continuous learning, and networking.

As a marker of our commitment to continuous education and professional development, this year's Conference program has been developed to align with the *Immunization Competencies for Healthcare Providers*. Developed by the Canadian Immunization Committee, a federal/provincial/territorial group of public health officials which provides advice and recommendations on the implementation of the National Immunization Strategy, the Immunization Competencies provide a framework for the development of formal and continuing education programs and best practice standards.

Since we last met in Winnipeg in 2006, HPV immunization programs have been rolled out in every province. This demonstrates the speed at which the immunization world moves, and underscores the importance of meetings like this one where we can share our knowledge and experiences, and determine the best path forward together.

I wish you all successful meetings, and I look forward to hearing the outcomes of this conference.

Sincerely,

Dr. David Butler-Jones,
Chief Public Health Officer,
Public Health Agency of Canada



Dear Conference Participants:

The Canadian Public Health Association is proud to be a collaborator in the 8th Canadian Immunization Conference: Partnership, Innovation and Education.

This is a pivotal time in the history of vaccines and immunization in Canada. Recent media coverage surrounding immunization issues and ongoing misconceptions reinforce the need for a strong, independent voice in support of immunization of children, adolescents and adults. The Canadian Public Health Association recognizes the key and vital role health professionals play in ensuring that immunization awareness and education remain at the forefront of the minds of policy makers, health professionals and the community at large.



The conference program is filled with excellent presentations from renowned experts, who will inspire, challenge and educate you. Each of you is an expert in your own right, so I encourage you to fully participate and share your expertise.

Please join me in thanking the members of the organizing committee and the conference secretariat for pulling everything together on our behalf.

I trust you will enjoy both the educational and networking value of this conference.

Sincerely,

Ron de Burger

Ron de Burger

Chair

Canadian Public Health Association





Welcome to Toronto!

It's always exciting to spend time with colleagues who are so passionate about infectious disease prevention. Over the many years that the Canadian Paediatric Society has been involved in the Canadian Immunization Conference, we've seen interest in immunization continue to grow — not just among health care professionals but among parents and the public as well.

As paediatricians, we play a critical role in ensuring that parents understand the importance of immunizing their children as we know that parents look to us for reliable and up-to-date information, and for assurance that vaccines are safe and effective. However, we also know that parents look to all health care professionals for this information and assurances as well.

The Canadian Immunization Conference is a chance to stay current on new developments and network with colleagues, both of which will help you help parents make informed decisions about their child's health and well-being.

Informed decision-making also requires credible resources. This week, the Canadian Paediatric Society is proud to be releasing the third edition of *Well Beings: A Guide to Health in Child Care*. This comprehensive reference is a must for child public health professionals, especially those who monitor and work with child care centres and home-based providers and who set policy. With so much information on the daily care, health and safety of children from birth to preschool, it is also an indispensable resource for physicians and parents alike. Visit our booth during the conference to peruse this essential reference.

On behalf of the Canadian Paediatric Society, I wish you a productive and enjoyable few days.

Joanne Embree, MD, FRCPC
 President
 Canadian Paediatric Society





Dear Conference Participants:

On behalf of the Canadian Association for Immunization Research and Evaluation, I welcome you to participate in and enjoy the many excellent scientific sessions organized for this conference.

The scientific venues include oral abstract presentations and posters. They offer an especially rich experience as more abstracts were submitted for this conference than for any previous one, resulting in two poster sessions. All abstracts have been peer-reviewed by experts from CAIRE, PHAC and the Abstract Review committee. Participants should feel welcome to question poster presenters during the designated poster viewing sessions and throughout the conference.

CAIRE is delighted to be an official partner in organizing the National Immunization Conference. This conference provides an important showcase for the research data generated by the Canadian community of vaccine researchers. It is critical that immunization programs and practice be built on a sound foundation of scientific research and evaluation. This requires an eye to the growth of the next generation of researchers. CAIRE is delighted that this year, a Vaccinology Student Research Program will be held in conjunction with the Canadian Immunization Conference. The student program has provided successful applicants with bursaries to attend the conference and an opportunity to present and discuss their research with selected experienced Canadian vaccinology researchers. The conference also provides important opportunities for researchers and practitioners to meet and network – there will be lots happening “behind the scenes” throughout the week.

My sincere thanks to the dozens of people who generously devoted their time and energy to the planning of the conference, the review of abstracts and student proposals, and the conduct of the scientific program. Now it's up to you, dear participant, to take advantage of the learning opportunities!

Margaret Russell

Margaret Russell, MD PhD

Chair, Abstract Review Committee

Co-Chair, Program Committee

Associate Professor, Community Health Sciences, U Calgary



A MESSAGE FROM THE MAYOR



It is my pleasure to extend greetings and a warm welcome to all delegates participating in the 8th Canadian Immunization Conference, hosted by the Public Health Agency of Canada.

This important conference brings together immunization experts from various disciplines to exchange and share information and knowledge, and discuss current trends and issues that shape and influence the industry.

This forum seeks to provide insight into emerging vaccinology science and its impact on practices and programs and will explore innovative approaches that lead to improvements in this field.

If you are visiting for this event, I encourage you to take some time to experience our vibrant neighbourhoods that reflect our multicultural diversity, enjoy our lively entertainment district and explore some of the interesting attractions our unique city has to offer.

On behalf of Toronto City Council, I congratulate the organizers of this event and wish everyone an informative and enjoyable conference and a memorable stay in Toronto.

David Miller, Mayor



TABLE OF CONTENTS



Conference Supporters.....	i
Welcome Messages.....	ii
General Information	1
About the Conference.....	1
Conference Goals	1
Learning	1
Continuing Medical Education Credits	1
Learning Tracks	1
Immunization Competencies for Health Professionals.....	3
Award Winners.....	4
Vaccinology Student Research Program	4
Travel Bursary	5
Conference Services	5
Interpretation Services.....	5
Free Influenza Immunization Clinic	5
Healthy-living Activities at the Conference.....	5
Sheraton Fitness Centre.....	5
Morning Energizers	6
Walking and Running Groups.....	6
Yoga Classes	6
Conference Policies.....	6
Disclosure of Conflict of Interest	6
Environmentally Friendly Delegate Bag.....	6
Scent-free Conference.....	6
Photo/Video Reproduction	6
Plenary and Workshop Attendance.....	7
Media/Media Room	7
Conference Secretariat.....	7
Speaker Ready Room/Lounge.....	7
Information	7
Conference Program	10
Program-at-a-Glance.....	12
Day-to-Day Program	13
Poster Listings.....	47
Satellite Symposia	55
Conference Organizing Committees	63
Program Committee	63
Operations Committee	64
Abstract Review and Adjudication Committee.....	64
Session Review and Conference Evaluation Committee.....	64
Travel Bursary Review Committee.....	65
Conference Coordination Team.....	65
Conference Secretariat	65
Track Your Learning!.....	66



GENERAL INFORMATION



About the Conference

The 8th Canadian Immunization Conference is organized by the Public Health Agency of Canada, Centre for Immunization and Respiratory Infectious Diseases in collaboration with the Canadian Association for Immunization Research and Evaluation (CAIRE), the Canadian Paediatric Society (CPS) and the Canadian Public Health Association (CPHA)

The Conference brings together non-governmental organizations, vaccine manufacturers, provincial and territorial immunization policy and program planners as well as professionals from the many disciplines involved in the immunization field.

Conference Goals

Through the conference theme, “Partnership, Innovation, Education”, the scientific program offers sessions that will help participants to:

- Gain insight into how emerging vaccinology science is contributing to the advancement in vaccines and immunization practices and programs;
- Learn scientific and programmatic information that will enhance participants’ knowledge in immunization for a safe and competent practice;
- Explore innovative approaches to improve immunization practice from concept to implementation; and
- Increase opportunities for networking, partnership and collaboration in the immunization field among participants.

LEARNING

Continuing Medical Evaluation Credits

This Conference is recognized by the CPS as an Accredited Group Learning Activity (section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Learning Tracks

The Conference is organized in a track-based format. Multiple workshops and featured sessions are offered for each of the eight learning tracks listed below. Learning Track Identifiers are found beside each session description.

COMM Communication of Risks and Benefits

By attending sessions under this learning track, participants will be able to:

- Explain the importance of risk perception for immunization decision-making;
- Deliver clear, concise messages about the risks of vaccine-preventable diseases and the benefits/risks of vaccines;
- Provide appropriate evidence-based information and resources to clients regarding immunization and vaccines; and
- Provide guidance to clients so they can correctly identify credible sources of information on immunization and vaccines.



EMERG Emerging Vaccine Science and its Implications for Immunization Programs

By attending sessions under this learning track, participants will be able to:

- Gain insight into how emerging vaccinology science is contributing to the advances in vaccines and immunization programs;
- Learn about various vaccinology research being conducted in Canada;
- Gain insight on how the advancements in the fields of innate immunity and adjuvant science are contributing to improvements in new vaccines and immunization programs; and
- Identify the challenges and opportunities for vaccinology and vaccination program development and effectiveness.

FLU Influenza

By attending sessions under this learning track, participants will be able to:

- Describe key data required for pandemic planning in Canada;
- Become familiar with Canadian research efforts to address knowledge gaps for pandemic planning/preparedness;
- Identify limitations of current inactivated influenza vaccine and understand strategies to address them;
- Become familiar with rationale and methodology for monitoring influenza immunization programs; and
- Advocate for the monitoring of influenza immunization programs.

INNOV Innovation in Vaccine Delivery

By attending sessions under this learning track, participants will be able to:

- Describe how promotion of immunization occurs at the front-line, community and societal levels;
- Identify innovative immunization program delivery strategies that can be used to optimize vaccine uptake in diverse population groups; and
- Identify ways that new immunization technology can enhance immunization uptake and schedule optimization.

LEGAL Legal and Ethical Aspects of Immunization

By attending sessions under this learning track, participants will be able to:

- Recognize the responsibility of immunizers to inform patients regarding the availability of all recommended vaccines regardless of whether or not they are publicly funded;
- Demonstrate the ability to provide vaccine-related information to clients in an unbiased way regardless of personal beliefs;
- Identify the basic ethical principles involved in informed consent and informed refusal; and
- Define the legal requirements of immunization practice in the provinces/territories that relate to immunization status and exclusion from day-care, school, workplace or other settings, and explain how these may be applied.

NEW New Vaccines from Concept to Implementation

By attending sessions under this learning track, participants will be able to:

- Learn the process to obtain marketing approval for vaccines in Canada;
- Distinguish between the responsibilities of industry, government (federal, provincial and territorial) and academia for new vaccine development and vaccine program introduction;
- Learn about some of the challenges around new vaccine development;
- Understand the role that public confidence can have on new vaccine program introduction; and
- Learn about the impact new vaccines can have on the burden of disease.

PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization

By attending sessions under this learning track, participants will be able to:

- Explain basic immunology; the composition of vaccines and their interaction with the immune system; and the role of vaccines in the prevention and control of vaccine-preventable diseases;
- Apply in the office and clinic settings, the basic core competencies required for the assessment of: individual immunization needs, for both routine and travel immunizations; vaccine storage and handling; informed consent; vaccine administration; documentation and reporting requirements in the office and clinic settings; and
- Understand the scientific and logistical rationale for the introduction and evaluation of publicly funded immunization programs.



PROMO Promotion of Immunization

By attending sessions under this learning track, participants will be able to:

- Specify the basic principles involved in vaccination promotion;
- Identify barriers (economic, educational, environmental and social factors) to immunization uptake;
- Recognize the importance of promoting vaccination among health professionals and the public and propose effective strategies to do so;
- Assess the vaccination promotion activities conducted at various levels of governments;
- Understand the components of the social marketing/education planning process including needs assessment, program planning, implementation and evaluation;
- Recognize the importance of understanding your target audience;
- Describe evidence-based multifaceted strategies to improve uptake;
- Identify data collection methods at different stages of the planning process in relation to budget;
- Appreciate the importance of field-testing for determining effectiveness of interventions before final implementation; and
- Understand the importance and challenges of evaluating social marketing initiatives to improve immunization uptake.

Immunization Competencies for Health Professionals

Developed to support the application of the National Guidelines for Immunization Practices which are published in the 7th Canadian Immunization Guide, the following 14 competencies range in topic from the scientific basis of immunization to essential immunization practices and contextual issues relevant to immunization. Each competency is supported by a learning domain and a number of guiding learning objectives. Please refer to your copy of the Immunization Competencies for Health Professionals found in your delegate bag.

The Immunization Competencies for Health Professionals are identified in this program using the following identifiers to guide participants as to which competencies are being addressed by each session.

Application of Basic Biomedical Sciences to Immunization

- | | |
|------------|--|
| IC1 | Explains how vaccines work using basic knowledge of the immune system. |
| IC2 | Demonstrates an understanding of the rationale and benefit of immunization. |
| IC3 | Integrates into practice knowledge about the main steps in vaccine development and evaluation. |
| IC4 | Applies the knowledge of the components and properties of immunizing agents as needed for safe and effective practice. |
| IC5 | Applies relevant principles of population health for improving immunization rates. |

Essential Immunization Practices

- | | |
|-------------|--|
| IC6 | Communicates effectively about immunization as relevant to the practice setting(s). |
| IC7 | Implements Canadian guidelines when storing, handling or transporting vaccines. |
| IC8 | Prepares and administers immunization agents correctly. |
| IC9 | Anticipates, identifies and manages adverse events following immunization. |
| IC10 | Documents information relevant to each immunization encounter in accordance with national guidelines for immunization practices and jurisdictional health information processes. |
| IC11 | Recognizes and responds to the unique immunization needs of certain population groups. |

Contextual Issues Relevant to Immunization

- | | |
|-------------|--|
| IC12 | Demonstrates an understanding of the Immunization System in Canada and its impact on the practice of health professionals. |
| IC13 | Addresses immunization issues using an evidence-based approach. |
| IC14 | Acts in accordance with legal and ethical standards in all aspects of immunization practice. |





AWARD WINNERS

2008 Canadian Immunization Poster Contest Award Ceremony

The Public Health Agency of Canada and the Canadian Coalition for Immunization Awareness & Promotion are pleased to present the 2008 Canadian Immunization Poster Contest. Grade 6 students from across Canada were invited to create posters expressing their ideas about immunization and healthy children. One national grand prize winner and one national runner-up were chosen, since one winner was chosen from each province and territory. We invite you to view all of the winning posters in the Exhibit Hall.

Prizes will be awarded to:

National Winner

The national grand prize winner, along with a parent or guardian, received an all-expense paid trip to Toronto to be recognized during the Opening Session of the 8th Canadian Immunization Conference on Sunday, November 30, 2008.

In addition, the national grand prize winner will receive an Apple 8GB iPod touch Digital media player, donated by BIOTECCanada Vaccine Industry Committee and an OWL Magazine gift bag, including *The Human Body* book, donated by Owl Kids.

The national grand prize winner's school will receive biotechnology/science materials for its library (estimated value \$500) donated by BIOTECCanada Vaccine Industry Committee.

National Runner-up

The national runner-up will receive a Pentax Optical Zoom Camera donated by BIOTECCanada Vaccine Industry Committee.

The national runner-up's school will receive biotechnology/science materials for its library, estimated value \$400, donated by BIOTECCanada Vaccine Industry Committee, as well as a copy of *Animal Adventures*, donated by OWL Magazine.

Provincial and Territorial Winners

Each provincial and territorial winner will receive a collection of art and school supplies donated by Lyreco.

All winning posters will be displayed at the 8th Canadian Immunization Conference, November 30 – December 3, 2008 in the Exhibit Hall and on the Conference site: www.publichealth.gc.ca/postercontest

Vaccinology Student Research Program

Four students were granted a bursary to attend the 8th Canadian Immunization Conference allowing them to participate in this new program lead by the Canadian Association for Immunization Research and Evaluation. Each student will have an opportunity to present and discuss their vaccinology research with experienced Canadian vaccinology researchers. Dr. Ethan Rubenstein served as coordinator of this program. The recipients are: Michael Campitelli, Andrea Kitta, Brian Reike and Katie Young.



GENERAL INFORMATION



Travel Bursary Program

The purpose of the travel bursary is to increase access to the conference for individuals or organizations with limited funding. The Travel Bursary Program's objective is to provide support to one individual per province/territory to attend the conference. The ability to select one representative per province/territory is dependent on the applications received. For the 2008 Conference, 11 bursaries were awarded to winners from across Canada.

Newfoundland/Labrador
Marlee Steel-Rodway

Nova Scotia
Deirdre Mombouquette

New Brunswick
Mariette Leblanc

Québec
Joanne Aube-Maurice
Vanessa Delisle

Ontario
Hong Ge

Manitoba
Michelle Johnson

Saskatchewan
Alexia Campbell

Alberta
Emily Medd
Alena Tse

Northwest Territories
Rebecca White

CONFERENCE SERVICES

Interpretation Services

Simultaneous interpretation will be provided in English and French free of charge to all Conference delegates. Simultaneous interpretation receivers and headphones may be obtained in the lobby beside the Conference Registration Desk. A valid piece of identification such as a current driver's license, credit card or passport will be required as a security deposit. To avoid unnecessary delays in obtaining receivers, it is highly recommended that receivers and headphones be obtained well in advance of each session. Receivers must be returned daily for recharging. Your identification will be returned upon presentation of the receiver and headphones. Loss or damage to equipment will result in replacement charges.

Free Influenza Immunization Clinic

Get your flu shot at the Conference! A free influenza immunization clinic will be open to all Conference delegates on Monday, December 1st, in the Second Floor lobby of the Sheraton Centre Toronto. This clinic is brought to you by the Toronto Public Health, Vaccine Preventable Diseases Program.

Healthy-living Activities at the Conference

Sheraton Fitness Centre

The use of the newly renovated and fully equipped, 2500 sq. ft. Fitness Centre at the Sheraton Centre is available to all delegates staying at the hotel. The charge is \$9.00 per day to a maximum of \$18.00 per stay. The Fitness Centre is available 24 hours a day, 7 days per week and features a relaxed environment overlooking terraced gardens and has direct access to the indoor/outdoor pool which can be used free of charge by hotel guests.



Morning Energizers

Staff of Toronto Public Health will lead morning energizers in the Plenary Room from 08:10 to 08:25 before the start of the day's plenary session. This light activity and stretching will have you moving around and ready for your day. Please join us!

Walking and Running Groups

A coordinator will be in the lobby of the Sheraton Centre on Monday, Tuesday and Wednesday mornings at 06:15 to organize running and walking groups wanting to get some exercise before the start of the day's sessions. The coordinator will have maps for 2k, 5k and 8k routes for all interested participants. Start your day off with some fresh air.

Yoga Classes

Yoga will be offered on Monday, Tuesday and Wednesday mornings from 06:30 to 07:30 in the Cosmopolitan Suite, 4th floor. Please come dressed in loose, comfortable clothing and bring your yoga mat or a towel.

CONFERENCE POLICIES

Disclosure of Conflict of Interest

All presenters have been asked to inform audience members attending the 8th Canadian Immunization Conference of any commercial interests that could present real or perceived conflicts of interest with the content of the material being presented. Such commercial interests could include, but are not limited to, employment, ownership of stock, membership on a standing advisory council or committee, or being on the board of directors or being publically associated with a company or its products. Other potential areas of real or perceived conflict of interest could include receiving honoraria, consulting fees or grants.

Environmentally Friendly Delegate Bag

Keeping the environment in mind, the Organizing Committee has chosen an Eco-tote bag for delegates this year. These bags are made of 90 grams of non-woven polypropylene, including 25% recycled material, making them biodegradable.

Scent-free Conference

The Public Health Agency of Canada and its organizing partners recognize that some people are sensitive to scented products and perfumes and strong odors which can precipitate severe reactions. We ask that delegates limit the use of perfumes, scented hair spray, cologne, aftershave and any other highly scented product out of respect for attendees with severe allergies. Please ensure that you adhere to the above policy. Thank you for your cooperation.

Photo/Video Reproduction

The Public Health Agency of Canada (PHAC) reserves the right to use any photo or video image recorded at the 8th Canadian Immunization Conference. By registering for the 8th Canadian Immunization Conference, you hereby acknowledge and agree that PHAC may photograph and/or videotape you at this event, as well as use these photographs and/or videotapes in any publication or media for future educational and promotional activities/materials without further notification of or any compensation to you. For example, selected images will assist in the promotion of future PHAC events and may be used in professional displays, advertisements, printed publications, and/or on the PHAC web site. By registering for the Conference, you also acknowledge and agree to waive any right to inspect or approve any future educational and promotional activities/materials that may include photographs and/or videotapes of you.



GENERAL INFORMATION



Plenary and Workshop Attendance

Only participants who have officially registered for the Conference will be permitted to attend plenary, concurrent and workshop sessions. Please wear your name badge at all times. There will be a \$50 administration fee to reissue lost name badges to officially registered participants.

Media/Media Room

All media personnel must register upon arrival. Media will be identified by orange name badges. Members of the media are observers at all sessions, and are asked to refrain from asking questions during the time allotted for paying participants. Should a member of the media wish to interview a speaker, the interview can be coordinated by one of our media relations advisors who will be identified by orange name badges and located in the Huron Room. Media relations advisors can also be contacted through Conference staff members located in the Kent Room, Second floor.

Conference Coordination Team

The staffed PHAC Conference Coordination Team will function from 07:00 to 18:30 November 30 – December 3, 2008 in the Kent Room, Second Floor. Conference and Secretariat staff can be identified by clear name badge holders, and will be located at the Registration Desk, Speaker Ready Room and all sessions. The Conference Project Manager, Beverley Webster, may be reached through any staff member. After-hour emergencies should be directed to Conference Secretariat staff through the Sheraton Centre Toronto telephone operator.

Speaker Ready Room/Lounge

A Speaker Ready Room/Lounge will be available to all speakers of plenary and concurrent breakout sessions. It will be located in the Wentworth Room, Second Floor and will be equipped with the necessary equipment to prepare presentations. Secretariat services will also be available to speakers, as will refreshments and a lounge area. Only registered speakers, along with their accompanying guests, will be permitted entry to this area.

Saturday, November 29	14:00 - 20:00
Sunday, November 30	08:00 - 18:00
Monday, December 1	06:30 - 17:00
Tuesday, December 2	06:30 - 17:00
Wednesday, December 3	07:00 - 11:00

Information

Information regarding activities of the Conference may be obtained at the Registration Desk.



PLENARY HIGHLIGHTS AND KEYNOTE SPEAKERS

Opening Session

Welcome and Introduction by Conference Co-chairs:

Dr. Arlene King
Director General
Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Ms. Debra Lynkowski
Chief Executive Officer
Canadian Public Health Association

Distinguished Guests

2008 Canadian Immunization Poster Contest Winner

Plenary I

Dr. John Waters Memorial Lecture Immunization: Past, Present and Future

This keynote lecture will provide a perspective on the “distance travelled” and the challenges and opportunities for the future of immunization in Canada.

Speaker:

Dr. David Scheifele
University of British Columbia

Plenary II

New Vaccines in Canada - From Concept to Implementation: The HPV Story

This plenary lecture will provide insight into the process to get vaccines authorized for sale in Canada and then implemented into publicly-funded immunization programs. The session will start with the regulation process that vaccines go through before receiving authorization for sale. Next, the lecture will discuss the steps involved in implementing an immunization program and review the roles of the National Advisory Committee on Immunization (NACI), the Canadian Immunization Committee (CIC), and the Provincial/Territorial/Federal Ministries of Health. The lecture will conclude with a case study of the HPV vaccine.

Speakers:

The Regulation of Vaccines

Dr. Alexandra Simniceanu
Health Canada

Implementation of Immunization Programs

Dr. Greg Hammond (retired)
Manitoba Health

The HPV Story

Dr. Simon Dobson
British Columbia Children's Hospital



Plenary III

Communicating the Benefits and Risks with Clarity and Confidence

The public is confused and over-whelmed by information. Almost every day a new study is published claiming that yet another contaminant has been found in our environment that constitutes a risk to public health. It is more important than ever to discuss such issues from an accurate scientific perspective. This session will provide new insights and strategies to help effectively communicate science to the public. Participants will also learn how risk communications methodology can be applied to convey the rigor of the science supporting the safety and efficacy of immunization.

Speakers:

Communicating Science to the Public

Dr. Paul A. Offit
Children's Hospital of Philadelphia

HPV Vaccine: Public Health Promise, Communications Challenge

Sarah Lawley
Public Health Agency of Canada

Demystifying the Science of Immunization

Dr. Joe Schwarcz
McGill University

Plenary IV

Celebrating Canadian Innovation in New Vaccines and Vaccine Delivery

Vaccine development targeting new diseases and population groups, new vaccine technologies and innovative delivery systems for vaccines, all lead to improvement of vaccine programs. This session will highlight the contributions Canada is making to the immunization field.

Speakers:

New Uses of Old Vaccines – Neonatal and Maternal Immunization

Dr. Scott A. Halperin
Dalhousie University

Protein Misfolding-specific Epitopes – New Targets for Immunotherapy

Dr. Neil Cashman
University of Toronto

Novel Adjuvants and Delivery Systems for Improving Vaccines

Dr. Lorne Babiuk
University of Alberta

The Pan-provincial Vaccine Enterprise (PREVENT) – A New Paradigm for Accelerating Vaccine Commercialization

Dr. Andrew Potter
University of Saskatchewan



Plenary V

Evidence Base for Immunization Programs including the *Distinguished Lecture in Canadian Immunization*

This lecture will focus on the need for evidence to inform vaccine safety, vaccine effectiveness and immunization programs.

Speakers:

Vaccine Safety – An Evidence-Based Primer

Dr. Barbara Law

Public Health Agency of Canada

Vaccine Effectiveness – Evidence of Impact

Dr. Philippe De Wals

Institut national de santé publique du Québec

Distinguished Lecture in Canadian Immunization: Evidence-based Decision Making for Vaccine Programs in Canada

Dr. Gaston De Serres

Institut national de santé publique du Québec

Plenary VI

Pandemic Influenza: Critical Knowledge Gaps and Canadian Efforts to Bridge Them

This plenary will focus on the knowledge gaps facing pandemic planners and will present research efforts being undertaken in Canada to address them.

Speakers:

Knowledge Gaps for Pandemic Planners

Dr. Bonnie Henry

British Columbia Centre for Disease Control

Overview of the Canadian Institutes of Health Research Funding Program

Carol Richardson

University of Western Ontario

Evaluation of Urban Triage Centers

Dr. David Johnson

Capital Health

Pandemic Ethics Research

Dr. Nuala Kenny

Dalhousie University

Plenary VII

The Bottom Line: Hot Topics & Ask the Experts

This plenary session will cover a variety of issues related to the basis of immunization; introduction and use of vaccines in publicly funded programs in Canada (programmatic issues), and issues related to immunization practices.





PROGRAM-AT-A-GLANCE

Saturday, November 29

14:00 – 20:00 Registration and Information Desk

Sunday, November 30

08:00 – 18:30 Registration and Information Desk Open
13:00 – 14:00 Opening Session - Welcome and Introduction
14:00 – 15:00 Plenary I: Dr. John Waters Memorial Lecture Immunization: Past, Present and Future
15:00 – 16:00 Health Break
15:00 – 19:00 Exhibit Hall and Poster Viewing
16:00 – 17:30 Concurrent Sessions
17:30 – 19:00 Welcome Reception and Networking

Monday, December 1

06:00 – 18:00 Registration and Information Desk Open
07:00 – 08:30 Satellite Symposia (2)
08:30 – 10:00 Plenary II: New Vaccines in Canada - from Concept to Implementation: The HPV Story
10:00 – 10:30 Health Break
10:00 – 16:00 Exhibit Hall and Poster Viewing
10:30 – 12:00 Plenary III: Communicating the Benefits and Risks with Clarity and Confidence
12:30 – 13:30 Buffet Lunch
12:30 – 13:30 Lunchtime Workshops
13:00 – 15:00 Concurrent Sessions
15:00 – 16:00 Health Break
16:00 – 17:00 Concurrent Sessions
18:30 – 19:30 Cash Bar Reception and Networking
19:30 – 22:00 Conference Banquet (Ticket Purchase Required)

Tuesday, December 2

06:00 – 18:00 Registration and Information Desk Open
07:00 – 08:30 Satellite Symposia (2)
08:30 – 10:00 Plenary IV: Celebrating Canadian Innovation in New Vaccines and Vaccine Delivery
10:00 – 10:30 Health Break
10:00 – 16:00 Exhibit Hall and Poster Viewing
10:30 – 12:30 Plenary V: Evidence Base for Immunization Programs Including the *Distinguished Lecture in Canadian Immunization*
12:30 – 13:30 Buffet Lunch
12:30 – 13:30 Lunchtime Workshops
13:30 – 15:30 Concurrent Sessions
15:00 – 16:00 Health Break
16:00 – 17:30 Concurrent Sessions
Free Evening

Wednesday, December 3

06:30 – 18:00 Registration and Information Desk Open
07:00 – 08:30 Satellite Symposium
08:30 – 10:00 Plenary VI: Pandemic Influenza: Critical Knowledge Gaps and Canadian Efforts to Bridge Them
10:00 – 10:30 Health Break
10:30 – 12:20 Plenary VII: The Bottom Line: Hot Topics & Ask the Experts
12:20 – 12:30 Closing Remarks

DAY-BY-DAY PROGRAM



Sunday, November 30, 2008

13:00-14:00 OPENING SESSION

Welcome and Introduction

Grand Ballroom West/Centre

Conference Co-chairs: Dr. Arlene King
Director General
Centre for Immunization and Respiratory Infectious Diseases
Public Health Agency of Canada

Ms. Debra Lynkowski
Chief Executive Officer
Canadian Public Health Association

Distinguished Guests

2008 Canadian Immunization Poster Contest

Co-chairs: Dr. David Butler-Jones
Public Health Agency of Canada

Dr. Bonnie Henry
British Columbia Centre for Disease Control

Dr. Susan Bowles
Dalhousie University

Winner of the 2008 Canadian Immunization Poster Contest:
Ryan Magee
Monsignor J.S. Smith School
Calgary, Alberta

14:00-15:00 PLENARY I – DR. JOHN WATERS MEMORIAL LECTURE

EMERG

IC2

IC3

Immunization: Past, Present and Future

Grand Ballroom West/Centre

Chair: Dr. Margaret Russell
Canadian Association for Immunization Research and Evaluation

This keynote lecture will provide a perspective on the “distance travelled” and the challenges and opportunities for the future of immunization in Canada.

By the end of the session, participants will:

- Appreciate the impact of immunization programs on the occurrence of vaccine-preventable diseases;
- Understand the contribution of research to the growth in impact and effectiveness of immunization programs; and
- Identify future challenges and opportunities for vaccinology science and immunization program development and effectiveness.

Dr. David Scheifele
University of British Columbia

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.

Sunday, November 30



15:00-16:00

HEALTH BREAK – EXHIBIT AND POSTER VIEWING

Osgoode Ballroom

16:00-17:30

CONCURRENT SESSION (1 OF 7)

IC13

Immunization Competencies for Health Professionals

Dominion Ballroom North

Chair: Lyne Cantin
Public Health Agency of Canada

The Immunization Competencies for Health Professionals will be formally released during the Opening Session of the Canadian Immunization Conference. The use of the *Immunization Competencies* may vary between and within provinces and territories across Canada due to differences in immunization programs, services and immunization providers. This session will present three regions of Canada that have used and incorporated the *Immunization Competencies for Health Professionals* into their respective activities.

Atlantic Region

In the Atlantic Region, consultation meetings with undergraduate education providers took place to identify opportunities and potential barriers that may impact integration of the competencies into university curricula. This presentation will provide a summary of the feedback received during the consultation and recommendations.

British Columbia

British Columbia Center for Disease Control (BC CDC) is using the *Immunization Competencies for Health Professionals* as a basis for developing an on-line immunization competency course and exam. This course will meet the educational requirements of the College of Registered Nurses of BC for nurses who are giving immunizations. This presentation will provide an overview of the course development process and a snapshot of one of the modules.

Alberta

Alberta Health Services, Edmonton Area is using the *Immunization Competencies for Health Professionals* to develop questions and scenarios designed to assess knowledge that may not be readily observable in daily practice. This presentation will provide an overview of the questions and scenarios used to elicit knowledge of immunization practice in accordance with best practice guidelines and the *Immunization Competencies for Health Professionals*.

By the end of the session participants will be able to specify how the Immunization Competencies can be used by:

- Specify how the Immunization Competencies can be used by:
 - Educational institutions and continuing education providers to conduct needs assessments; assess existing curriculum, and incorporate the Immunization Competencies in undergraduate and continuing education training; and
 - Coordinators and managers of immunization programs to set practice standards and conduct employee performance evaluations.

Integrating *Immunization Competencies for Health Professionals* into Undergraduate Nursing Programs

Dr. Donna Pierrynowski Gallant
Canadian Centre for Vaccinology, Halifax

Using the *Immunization Competencies for Health Professionals* as a basis for developing an on-line immunization course for BC nurses

Carlin Miroslaw
British Columbia Centre for Disease Control

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

Sunday, November 30

DAY-BY-DAY PROGRAM



Using the *Immunization Competencies for Health Professionals* for Knowledge and Skills Assessment

Joy Loewen
Alberta Health Sciences, Edmonton Area

16:00-17:30 CONCURRENT SESSION (2 OF 7)

PRIMER

IC6

IC11

Travel Health - A Primer for Front Line Providers

Dominion Ballroom South

Chair: Dr. Pierre Plourde
Winnipeg Regional Health Authority

This session will provide an overview of practical clinical setting issues related to vaccine for travellers.

By the end of the session participants will be able to:

- Apply the national or provincial guidelines that guide travel immunization to meet the unique immunization needs of the traveller;
- Deliver clear concise messages about benefits and risks of select travel-related vaccines;
- Understand immunization considerations for “special” travellers; and
- Identify where to find expert advice regarding travel immunization and recommendations.

The Basics – Idiot's Guide to Travel Vaccines

Dr. Pierre Plourde
Winnipeg Regional Health Authority

Travel Vaccines That Aren't Black and White

Dr. Brian Ward
McGill University Vaccine Evaluation Centre

Special Considerations for Special Populations

Dr. Mark Wise
The Travel Clinic

16:00-17:30 CONCURRENT SESSION (3 OF 7)

Oral Abstracts

Grand Ballroom East

Co-chairs: Gordean Bjornson
Canadian Association for Immunization Research and Evaluation

Dr. David Scheifele
University of British Columbia

O01 Changes in the Epidemiology of Invasive Pneumococcal Disease (IPD) Following Implementation of a 7-Valent Pneumococcal Conjugate Vaccine (PCV7) Program in Québec, Canada

Dr. Philippe De Wals
Université Laval

O02 The Effect of Routine Vaccination on Invasive Pneumococcal Infection in Canadian Children: 2000-2007, A Report From the IMPACT Network

Julie Bettinger
British Columbia Children's Hospital - Vaccine Evaluation Centre

O03 Anti-HBS and Immune Memory 10 Years After the Vaccination of Preadolescents with Engerix-B
Vladimir Gilca
Direction régionale de santé publique de la Capitale nationale

O04 Dose-Ranging Study of a Subunit RSV Vaccine in the Elderly
Dr. Joanne Langley
Dalhousie University

O05 Real-Time Post-Marketing Surveillance of Influenza Vaccine Safety and Immunogenicity
Dr. Barbara Law
Public Health Agency of Canada

O06 Selection Bias in the Measure of Vaccine Protection Against Serious But Non-Specific Influenza Outcomes in Seniors: Examination Through Linked Manitoba Databases
Travis Salway Hottes
British Columbia Centre for Disease Control

16:00-17:30

CONCURRENT SESSION (4 OF 7)

- COMM
- IC5
- IC6

HPV Lessons Learned

Civic Ballroom

Chair: Rosalie Tuhscherer
Saskatchewan Ministry of Health

This session examines communication lessons learned from the implementation of new HPV immunization programs in some jurisdictions. The session will begin by highlighting the importance of a well-coordinated communications plan to ensure that the population has access to reliable and accurate immunization information to facilitate decision-making for protection against vaccine-preventable diseases. The second part of the session will propose communication strategies that support individual informed decisions.

By the end of this session, participants will:

- Understand the importance of risk perception for immunization decision making;
- Describe selected communication and health promotion strategies to improve immunization coverage rates; and
- Use effective communication strategies to answer the difficult questions from teens and their parents regarding the HPV vaccine.

When Policy Hits the Front Line

Dr. Ian Gemmill
Kingston, Frontenac and Lennox & Addington Public Health

Counselling Teens and Their Parents

Dr. Simon Dobson
British Columbia Children's Hospital

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

DAY-BY-DAY PROGRAM



16:00-17:30

CONCURRENT SESSION (5 OF 7)

COMM

Journal Club: The Top Significant Articles in 2008

Chair: Marie Adèle Davis
Canadian Paediatric Society

This session will identify the top 5-10 relevant articles for front line immunization providers of journal articles published in 2008.

Dr. Ben Tan
Royal University Hospital

Karen Pielak
British Columbia Centre for Disease Control

Sunday, November 30

16:00-17:30

CONCURRENT SESSION (6 OF 7)

PROMO

IC5

IC6

Leveraging Social Media Tools and Web 2.0 Technologies: Moving from BIG BANG to Small Bang Communications

Essex Ballroom

Co-chairs: Marquis Côté
Public Health Agency of Canada

Mark Hudson
Public Health Agency of Canada

This session will offer a thought-provoking lecture about the impact of social media and Web 2.0 on communications for the public, private and non-profit sectors. Drawing from a mix of research, web traffic data and live case studies, this workshop will present some concepts that will make you say “wow” and spark debates on how you could embrace this brave new communication dimension.

Challenges that social media and Web 2.0 present include:

- Maintaining message “control” and information integrity in a distributed channel environment;
- How, where and when to prioritize effort and investments;
- Living up to stakeholder expectations in a rapidly evolving technology environment; and
- The increasingly important role of Wikipedia.

By the end of this session, participants will gain knowledge about:

- Web 2.0 and social media;
- Some of the more important social media tools and Web 2.0 technologies;
- How other organizations are leveraging these tools to support their mission and goals; and
- Communication strategies in a fragmented media world.

Anti-immunization Messages on Social Media

Dr. Vera Pavri-Garcia
York University

Leveraging Social Media Tools and Web 2.0 Technologies: Moving from BIG BANG to Small Bang Communications

Dr. Alex Langshur
PublicInsite

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.



DAY-BY-DAY PROGRAM

Sunday, November 30

16:00-17:30

CONCURRENT SESSION (7 OF 7)

- PRIMER
- IC6
- IC7
- IC8
- IC9
- IC10
- IC14

From Fridge to Arm in 5 “Easy” Steps *(This session is repeated on Monday)* **Grand Ballroom West/Centre**

Chair: Dr. Shelley Rechner
The College of Family Physicians of Canada

This session will present a series of updates on current practice issues related to immunization and vaccine safety. Topics will include vaccine storage, communications strategies, informed consent, multiple immunizations, and adverse event management and documentation.

- By the end of the session, participants will be able to:
- Apply the national guidelines for vaccine storage, handling and transportation to their practice settings;
 - Communicate effectively to obtain informed consent;
 - Use strategies to decrease client and provider stress regarding multiple injections;
 - Differentiate and describe anaphylaxis versus a temporal vaso-vagal response post-immunization and identify actions for immediate and post-situation management; and
 - Explain rationale for immunization documentation guidelines as per the *Canadian Immunization Guide*.

Vaccine Storage and Handling
 Alexandra Henteleff
Manitoba Health

Informed Consent
 Dr. Noni MacDonald
Dalhousie University

Strategies for Multiple Injections
 Cindy Dribnenki
Alberta Health and Wellness

Immediate Post-Immunization Adverse Event Management
 Dr. Shelley Rechner
The College of Family Physicians of Canada

Documentation
 Alexandra Henteleff
Manitoba Health

Managing the Call About the Adverse Events
 Dr. Shelley Rechner
The College of Family Physicians of Canada

17:30-19:00

WELCOME RECEPTION AND NETWORKING
 EXHIBIT AND POSTER VIEWING

Osgoode Ballroom, Sheraton Hall

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

DAY-BY-DAY PROGRAM



Monday, December 1, 2008

07:00-08:30 SATELLITE SYMPOSIUM

Advances in Influenza Vaccination

Dominion Ballroom, North/South

This session has been co-developed by the Canadian Paediatric Society and sanofi pasteur.
Please refer to the Satellite Symposia section for details.

07:00-08:30 SATELLITE SYMPOSIUM

A Pneumococcal Vaccine Program Report Card: "A" Student or Summer School Attendee? **Civic Ballroom**

This session has been co-developed by Canadian Paediatric Society and Wyeth.
Please refer to the Satellite Symposia section for details.

08:30-10:00 PLENARY II

NEW

IC12

New Vaccines in Canada - From Concept to Implementation: The HPV Story **Grand Ballroom West/Centre**

Chair: Dr. Harold Rode
Health Canada

This plenary lecture will provide insight into the process to get vaccines authorized for sale in Canada and then implemented into publicly-funded immunization programs. The session will start with the regulation process that vaccines go through before receiving authorization for sale. Next, the lecture will discuss the steps involved in implementing an immunization program and review the roles of the National Advisory Committee on Immunization (NACI), the Canadian Immunization Committee (CIC), and the Provincial/Territorial/Federal Ministries of Health. The lecture will conclude with a case study of the HPV vaccine.

Participants attending this plenary session will be able to:

- Describe the process vaccines must undergo to receive market authorization and the steps involved in introducing recently authorized vaccines into new publicly-funded immunization programs in Canada; and
- Explain the role and responsibilities of the jurisdictions and committees involved in the implementation of immunization programs in Canada.

The Regulation of Vaccines

Dr. Alexandra Simniceanu
Health Canada

Implementation of Immunization Programs

Dr. Greg Hammond (retired)
Manitoba Health

The HPV Story

Dr. Simon Dobson
British Columbia Children's Hospital

Monday, December 1



DAY-BY-DAY PROGRAM

Monday, December 1

10:00-10:30 HEALTH BREAK – EXHIBIT AND POSTER VIEWING **Osgoode Ballroom, Sheraton Hall**

10:30-12:30 PLENARY III

- COMM**
- IC5**
- IC6**
- IC13**

Communicating the Benefits and Risks with Clarity and Confidence **Grand Ballroom West/Centre**

Chair: Dr. Allison McGeer
Mount Sinai Hospital

The public is confused and over-whelmed by information. Almost every day a new study is published claiming that yet another contaminant has been found in our environment that constitutes a risk to public health. It is more important than ever to discuss such issues from an accurate scientific perspective. This session will provide new insights and strategies to help effectively communicate science to the public. Participants will also learn how risk communications methodology can be applied to convey the rigor of the science supporting the safety and efficacy of immunization.

- By the end of this session, participants will be able to:
- Explain the basic principals of benefit-risk communication;
 - Deliver clear, concise messages about the risks of vaccine-preventable diseases and the benefits and risks of vaccines;
 - Explain and communicate evidence-based information to the public regarding immunization programs and vaccines; and
 - Apply strategies and tools of risk communications to assist their organizations in the successful management of risk issues.

Communicating Science to the Public

Dr. Paul A. Offit
Children's Hospital of Philadelphia

HPV Vaccine: Public Health Promise, Communications Challenge

Sarah Lawley
Public Health Agency of Canada

Demystifying the Science of Immunization

Dr. Joe Schwarcz
McGill University

12:30-13:30 BUFFET LUNCH – EXHIBIT AND POSTER VIEWING **Osgoode Ballroom, Sheraton Hall**

12:30-13:30 LUNCHTIME WORKSHOP **Windsor West**
Refer to page 45 for details

Learning Tracks			
COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation
		PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
		PROMO	Promotion of Immunization

DAY-BY-DAY PROGRAM



13:30-15:00

CONCURRENT SESSION (1 OF 7)

PRIMER

IC1

IC4

IC5

Vaccinology: Update for Immunizers *(This session is repeated on Tuesday)*

Chair: Dr. Shelly McNeil
Dalhousie University

Dominion Ballroom North

Competent immunization delivery requires both an understanding and an ability to communicate basic principles of immunology, vaccine components and properties, and population health. In this session, participants will learn the basics of the immune response to vaccines, how the type of vaccine and its components may influence the immune response, and key principles of population health relevant to immunization and to optimizing immunization coverage rates.

By the end of this session participants will be able to:

- Explain how vaccines work using a basic knowledge of the immune system;
- Describe host and vaccine factors that influence the immune response to vaccines;
- Respond to concerns that giving too many vaccines will overwhelm the immune system;
- Compare the major advantages and disadvantages of live attenuated versus inactivated / subunit immunizing agents; and
- Explain the concept of herd immunity (also called community immunity) in non-scientific terms.

Vaccine Type and Composition: Why do I need to know?

Marina Salvadori
Children's Hospital of Western Ontario

Population Health for Immunizers: A Primer

Dr. Geneviève Petit
Direction de santé publique et de l'évaluation

13:30-15:00

CONCURRENT SESSION (2 OF 7)

EMERG

IC1

IC4

Innate Immunity and Toll-Like Receptor Signaling: Critical Aspects of Protection Against Infection and Its Implications for Vaccines

Chair: Dr. Stuart Turvey
University of British Columbia

Dominion Ballroom South

This session will cover the innate immune system and the role of Toll-like receptors (TLR) in fighting infections. Participants will learn how Toll-like receptor ligands are being used as adjuvants to improve the immune response to vaccines.

By the end of this session, participants will be able to:

- Understand the human innate immune system;
- Appreciate the role of innate immunity and Toll-like receptor signalling in protecting people from infectious diseases; and
- Comprehend how adjuvants improve vaccine immunogenicity by stimulating the innate immune response.

Monday, December 1



Toll-like Receptors: Sentinels of Host Defense Against Bacterial Infections

Dr. Salman Qureshi
McGill University

Role of TLR Ligands as Adjuvants in Pneumococcal Vaccines

Dr. Clifford M. Snapper
Uniformed Services University of the Health Sciences

Introduction of Innate Immunity and TLR Signaling

Dr. Stuart Turvey
University of British Columbia

13:30-15:00

CONCURRENT SESSION (3 OF 7)

COMM

IC6

IC13

Responding to the Media

Chair: Dr. Susan Bowles
Canadian Pharmacists Association

Grand Ballroom East

The first part of this session will focus on how to deal with positive and negative media reports concerning immunization issues. Specific case examples involving the HPV vaccine, vaccine shortages, mismatch in influenza vaccines, and vaccine safety/efficacy in pregnancy will be highlighted.

The second part of the session will use case examples to describe a current working model developed to provide front line professionals with a real-time response to patient inquiries arising from media reports. Specific case examples will be highlighted in this segment as well.

By the end of the session, participants will be able to:

- Describe strategies that can be used to respond to positive or negative media reports about immunization issues;
- Recognize the expertise and resources in place at the Drug Information and Research Centre to provide a real-time response to immunization inquiries from frontline professionals; and
- Explain how a current working model is able to provide a real-time response to front line professionals when dealing with patient inquiries arising from media reports.

Responding to the Media

Dr. Allison McGeer
Mount Sinai Hospital

Real-time Response

Susan Halasi
Ontario Pharmacists Association

13:30-15:00

CONCURRENT SESSION (4 OF 7)

NEW

IC3

What Drives New Vaccine Development: Who Gets to Decide What Conditions are Targeted?

Civic Ballroom

Chair: Dr. Brian Ward
McGill University

Learning Tracks

COMM

Communication of Risks and Benefits

INNOV

Innovation in Vaccine Delivery

PRIMER

Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization

EMERG

Emerging Vaccine Science and its Implications for Immunization Programs

LEGAL

Legal and Ethical Aspects of Immunization

PROMO

Promotion of Immunization

FLU

Influenza

NEW

New Vaccines from Concept to Implementation

DAY-BY-DAY PROGRAM



In this session, the issue of how conditions are targeted for vaccine development will be addressed from the three very different perspectives of those working in public health, academia and industry. The speakers will discuss the actual processes involved in targeting conditions for vaccine development and how conditions could ideally be targeted.

By the end of the session participants will:

- Demonstrate knowledge of the complex issues involved in vaccine development;
- Distinguish three different sets of priorities for vaccine development; and
- Understand what factors influence the vaccine development “pipeline”.

Industry

Dr. David Burt
GlaxoSmithKline

Public Health

Dr. Danuta Skowronski
British Columbia Centre for Disease Control

Academia

Dr. Brian Ward
McGill University

13:30-15:00

CONCURRENT SESSION (5 OF 7)

INNOV

IC5

IC11

Immunization Promotion and Delivery: Reaching Diverse Populations - Part I

City Hall

Chair: Gina Dumaresq
Health Canada

Immunization providers and health promoters use a range of techniques to increase uptake of immunization in the diverse populations they work with. Guided by the Ottawa Charter for Health Promotion, this session will explore a variety of tools and techniques used by front line health professionals to address immunization promotion and delivery at community and societal levels. The ideas presented will be transferable across numerous diverse populations.

By the end of the session participants will:

- Recognize the various levels of intervention that support immunization uptake;
- Understand unique ways in which diverse client groups have been reached with immunization promotion activities; and
- Identify tools and techniques to enhance access to immunization programs for diverse client groups.

Creating Supportive Environments: Outreach to the Homeless Population in Calgary

Dr. Judy MacDonald
Calgary Health Region

Strengthening Community Action: Immunization for Refugees and New Canadians

Dr. Meb Rashid
Access Alliance Multicultural Community Health Centre

Monday, December 1



Developing Personal Skills: Increasing Immunization in First Nations Communities

Lea Bill
Health Canada

13:30-15:00

CONCURRENT SESSION (6 OF 7)

FLU
IC4

Building a Better Influenza Vaccine

Essex Ballroom

Chair: Dr. Joanne Langley
National Advisory Council on Immunization

This session will address the challenges in selecting influenza strains for inclusion in seasonal influenza vaccines and some of the options for improving this process. Participants will learn about new adjuvants, delivery systems and novel vaccines being developed to improve the effectiveness of seasonal influenza vaccine.

By the end of the session, participants will:

- Recognize the progress in the selection of appropriate antigens for the trivalent influenza vaccine for the Northern hemisphere;
- Understand how alternative adjuvants, doses and delivery routes may enhance the immunogenicity of seasonal influenza vaccine; and
- Be aware of developments in the science of vaccines which use conserved protein antigens rather than surface antigens (H, N).

How Does National and International Influenza Surveillance Inform Annual Antigen Selection?

Dr. Alexander Klimov
Centers for Disease Control and Prevention

Improving Immunogenicity and Effectiveness to Influenza Surface Glycoproteins H and N: The Role of Dose, Adjuvants and Other Strategies

Dr. Wendy Keitel
Baylor College of Medicine

Influenza Vaccines Using Internal Virion Proteins - Is a Better Vaccine on the Horizon?

Dr. Francisco Diaz-Mitoma
Children's Hospital of Eastern Ontario

13:30-15:00

CONCURRENT SESSION (7 OF 7)

PRIMER
IC6
IC7
IC8
IC9
IC10
IC14

From Fridge to Arm in 5 "Easy" Steps (This session is repeated from Sunday)

Grand Ballroom West/Centre

Chair: Alexandra Henteleff
Manitoba Health

This session will present a series of updates on current practice issues related to immunization and vaccine safety. Topics will include vaccine storage, communications strategies, informed consent, multiple immunizations, and adverse event management and documentation.

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

Monday, December 1

By the end of the session, participants will be able to:

- Apply the national guidelines for vaccine storage, handling and transportation to their practice settings;
- Communicate effectively to obtain informed consent relevant to both the practice setting and the client;
- Use strategies to decrease client and provider stress regarding multiple injections;
- Differentiate and describe anaphylaxis versus a temporal vaso-vagal response post-immunization and identify actions for immediate and post-situation management; and
- Explain the rationale for immunization documentation guidelines as per the *Canadian Immunization Guide*.

Vaccine Storage and Handling

Alexandra Henteleff
Manitoba Health

Informed Consent

Dr. Noni MacDonald
Dalhousie University

Strategies for Multiple Injections

Cindy Dribnenki
Alberta Health and Wellness

Immediate Post-Immunization Adverse Event Management

Dr. Shelley Rechner
The College of Family Physicians of Canada

Documentation

Alexandra Henteleff
Manitoba Health

Managing the Call About the Adverse Events

Dr. Shelley Rechner
The College of Family Physicians of Canada

Monday, December 1

15:00-16:00 HEALTH BREAK – EXHIBIT AND POSTER VIEWING Osgoode Ballroom, Sheraton Hall

16:00-17:30 CONCURRENT SESSION (1 OF 6)

PRIMER

IC12

The Evidence for Program Decisions: Surveillance, Epidemiology, Disease, Impact, Modeling, Economics *(This session is repeated on Tuesday)*

Dominion Ballroom North

Chair: Dr. Bonnie Henry
British Columbia Centre for Disease Control

This session will review a framework for assessing vaccines for publicly funded programs and will use two examples of practical application of the framework to enhance understanding of how program decisions are made in Canada.

By the end of the session, participants will have gained knowledge about:

- The framework that is used to assess candidate vaccines for publicly funded programs;
- How advisory committees make recommendations on vaccine programs; and
- The factors that affect the decision to initiate publicly funded vaccine programs and the process to implement them.

A Primer on the Framework for Assessing Vaccine Programs

Dr. Philippe De Wals
Université Laval

Using Evidence to Implement a Vaccine Program Cost Effectively: The Prevnar Story

Cheryl McIntyre
British Columbia Centre for Disease Control

Changing Programs: Epidemiology & Economics: The Twinrix™ Story in Quebec

Dr. Vladimir Gilca
Direction régionale de santé publique de la Capitale nationale

16:00-17:30

CONCURRENT SESSION (2 OF 6)

Oral Abstracts

Co-chairs: Dr. Jeff Kwong
Institute for Clinical and Evaluative Sciences

Dr. Scott Halperin
Dalhousie University

Civic Ballroom

O07 Public Health Governance 1997-2008: The Case of Canadian Immunization Policy

Catherine Mah
University of Toronto

O08 Epidemiology of Measles Outbreak in Toronto 2008

Michael Finkelstein
Toronto Public Health

O09 MMR Vaccine Reactions: The Alberta Experience

Cindy Dribnenki
Alberta Health and Wellness

O10 Kinetics of the IGG And IGA Antibody Response in Post-Partum Women After Immunization With TDAP

Beth Halperin
Dalhousie University

O11 Impact of a 2-Day Interactive Instructional Intervention on the Use of Proactive Vaccination Practices Among Nurses Working in Community Health Centers

Dr. Geneviève Petit
Université de Sherbrooke

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

DAY-BY-DAY PROGRAM



O12 Communication Skills Training in Vaccine Related Issues During Pediatric Residency
Athena McConnell
University of Saskatchewan

16:00-17:30

CONCURRENT SESSION (3 OF 6)

COMM

The A.S.K. Approach to Immunization Communication: Communication Tools and Strategies for the Front Line

Grand Ballroom East

IC6

Chair: Mary Appleton

IC13

Canadian Center for Vaccinology

This workshop will provide participants with practical tips for communicating with parents using the **A.S.K.** approach - **A**cknowledge client concerns, **S**teer the conversation, **K**now the facts well - developed by the communication sub-committee of the BC Immunization Promotion Working Group. Using a round table discussion format, participants will be challenged to compose answers to typical questions from the public. Participants will receive a resource and tools for implementation in their practice setting.

By the end of this workshop, participants will be able to:

- Apply a systematic method for answering difficult immunization questions that corrects misinformation, communicates a benefit statement and reassures clients of the high level of immunization safety;
- Demonstrate immunization communication skills and confidence in a safe practice setting;
- Use plain language to provide information that enables informed decision making;
- Tailor communications to ensure information matches a client's individual needs; and
- Demonstrate knowledge about the many ways messages are communicated and the importance of being an effective communicator.

Andrea Derban
British Columbia Centre for Disease Control

Lisa Jarvos
Fraser Health Authority

Donna McNeil
Vancouver Island Health Authority

Jamie Pringle
Vancouver Coastal Health

Ian Roe
British Columbia Centre for Disease Control

Joanne Smrek
Penticton Health Centre

Margot Smythe
Vancouver Coastal Health

Monday, December 1



16:00-17:30

CONCURRENT SESSION (4 OF 6)

NEW
IC3

New Challenges and Advances in Vaccine Development

City Hall

Chair: Dr. Bhagirath Singh
Canadian Institutes for Health Research

Even with the tremendous increase in our understanding of host immune responses, the sequencing of pathogen genomes, and other technological advances, important hurdles remain towards our ability to develop and deploy vaccines for a variety of diseases. This session will bring together experts on specific diseases to present their views on the scientific and technical challenges that continue to exist and limit the development and utilization of effective vaccines against many diseases.

By the end of the session participants will:

- Recognize the scientific challenges encountered by vaccine experts developing vaccines against diseases such as AIDS, Hepatitis C and TB;
- Appreciate the role of non-conventional approaches in the development of vaccines for infectious diseases; and
- Gain insight into the global effort needed to develop such vaccines.

Progress Toward the Development of an HIV Vaccine

Dr. Alan Bernstein
Global HIV Vaccine Enterprise

Challenges in Vaccine Design for HCV; *in Vitro* vs *in Vivo*; Mouse vs Man

Dr. Babita Agrawal
University of Alberta

What's New in TB Vaccine Development?

Dr. Marcel Behr
Montreal General Hospital

16:00-17:30

CONCURRENT SESSION (5 OF 6)

INNOV
IC5
IC11

Immunization Promotion and Delivery: Reaching Diverse Populations - Part II **Dominion Ballroom South**

Chair: Gina Dumaresq
Health Canada

Immunization providers and health promoters use a range of techniques to increase uptake of immunization in the diverse populations they work with. Guided by the Ottawa Charter for Health Promotion, this session will explore a variety of tools and techniques used by front line health professionals to address immunization promotion and delivery at community and societal levels. The ideas presented will be transferable across numerous diverse populations.

By the end of the session participants will:

- Recognize the various levels of interventions that support immunization uptake;
- Understand unique ways in which diverse client groups have been reached with immunization promotion activities; and
- Identify tools and techniques to enhance access to immunization programs for diverse client groups.

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

Monday, December 1

DAY-BY-DAY PROGRAM



Reorienting Health Care Services: Use of Continuous Quality Improvement Strategies to Increase Immunization Coverage Rates

Nathan Crawford

Centers for Disease Control and Prevention, Atlanta

Building Healthy Public Policy: Use of Alternative Providers in Remote/Isolated Settings

Gina Carpenter

Bristol Bay Area Health Corporation

Reorienting Health Care Services: Improving Immunization Service Delivery in First Nation Communities

Patricia Huntly

Health Canada

16:00-17:30

CONCURRENT SESSION (6 OF 6)

FLU

IC3

IC4

IC5

Monitoring Influenza Vaccine Programs: How Can We Do Better?

Essex Ballroom

Chair: Dr. Gaston De Serres

Institut national de santé publique du Québec

Influenza immunization programs have become increasingly larger and more complex as target populations have continued to expand. Monitoring the major components of the influenza immunization program is critical in assessing whether the tremendous resources spent annually are achieving program objectives. This session will examine traditional and novel methodologies utilized to monitor the three most important components of the influenza program: effectiveness, safety and vaccine coverage rates.

At the end of the session participants will be able to:

- Explain the reasons for the annual variability in the effectiveness of the influenza vaccine;
- Describe the components of the national vaccine safety surveillance system; and
- Describe the current level of vaccine coverage and identify the most important obstacles to increasing it.

Monitoring Vaccine Effectiveness

Dr. Danuta Skowronski

British Columbia Centre for Disease Control

Monitoring Vaccine Safety

Dr. Barbara Law

Public Health Agency of Canada

Monitoring Vaccine Control

Dr. Maryse Guay

Institut national de santé publique du Québec

Monday, December 1



DAY-BY-DAY PROGRAM

18:30-19:30

CASH BAR RECEPTION AND NETWORKING

Grand Ballroom Foyer

19:30-22:30

CONFERENCE BANQUET

Grand Ballroom West/Centre

The BIOTECanada Vaccine Industry Committee presents Dr. Roberta Bondar: astronaut, physician, scientific researcher.

An electrifying speaker with groundbreaking insight on innovation, discovery, leadership and high-performance thinking, Roberta Bondar has been inspiring audiences for more than a decade as one of North America's most sought-after and respected presenters. Dr. Bondar will address delegates on the dynamic of biotech discovery and the opportunities it presents for medical practitioners and patients.

This year's banquet features live music by the George St. Kitts Band, a 9-piece band led by Mr. George St. Kitts, a much sought-after entertainer whose background includes performances in *The Lion King*, *The Rat Pack*, *Soul to Soul* and *Once on this Island*. For more information about the band, please visit their Web site at www.stkittsmusic.ca

Monday, December 1

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

DAY-BY-DAY PROGRAM



Tuesday, December 2, 2008

07:00-08:30

SATELLITE SYMPOSIUM

Update on the control of Invasive Meningococcal Disease in Canada and the use of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Against Serogroups A, C, Y, and W-135

Dominion Ballroom, North/South

This session has been co-developed by the Canadian Paediatric Society and sanofi pasteur.
Please refer to the Satellite Symposia section for details.

07:00-08:30

SATELLITE SYMPOSIUM

Zoster and Post-Herpetic Neuralgia: Is this a Disease Worth Preventing? A Burning Question.

Civic Ballroom, North/South

This session has been co-developed by the Canadian Paediatric Society and Merck Frosst Canada.
Please refer to the Satellite Symposia section for details.

08:30-10:00

PLENARY IV

EMERG

IC3

IC4

Celebrating Canadian Innovation in New Vaccines and Vaccine Delivery

Grand Ballroom West/Centre

Chair: Dr. Scott A. Halperin
Dalhousie University

Vaccine development targeting new diseases and population groups, new vaccine technologies and innovative delivery systems for vaccines, all lead to improvement of vaccine programs. This session will highlight the contributions Canada is making to the immunization field.

By the end of the session participants will be able to:

- Recognize Canada's contribution to the wide array of new vaccine technologies and new uses for current vaccines that will be introduced in the near future;
- Identify Canada's contribution to vaccines for new target diseases from prions to more traditional targets such as Chlamydia infections;
- Describe Canada's contribution to new vaccine technology like adjuvants and different delivery systems for vaccines; and
- Explain changes that may be coming in the future for vaccines and vaccine programs in Canada using knowledge gained in this session.

New Uses of Old Vaccines – Neonatal and Maternal Immunization

Dr. Scott A. Halperin
Dalhousie University

Protein Misfolding-Specific Epitopes – New Targets for Immunotherapy

Dr. Neil Cashman
University of Toronto

Novel Adjuvants and Delivery Systems for Improving Vaccines

Dr. Lorne Babiuk
University of Alberta

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.

Tuesday, December 2



The Pan-provincial Vaccine Enterprise (PREVENT) – A New Paradigm for Accelerating Vaccine Commercialization

Dr. Andrew Potter
University of Saskatchewan

10:00-10:30 HEALTH BREAK – EXHIBIT AND POSTER VIEWING **Osgoode Ballroom, Sheraton Hall**

10:30-12:30 PLENARY V

- IC2**
- IC3**
- IC6**
- IC9**
- IC12**
- IC13**

Evidence Base for Immunization Programs including the *Distinguished Lecture in Canadian Immunization*

Grand Ballroom West/Centre

Chair: Dr. Arlene King
Public Health Agency of Canada

This lecture will focus on the need for evidence to inform vaccine safety; vaccine effectiveness and immunization programs.

Vaccine Safety – An Evidence-based Primer

By the end of the session, participants will be able to:

- Distinguish between reporting an adverse event following immunization and proving that immunization caused an adverse event;
- Describe the types of evidence that inform vaccine safety and discuss their relative strengths and weaknesses;
- Locate evidence-based sources of information on current issues related to vaccine safety; and
- Incorporate the scientific evidence into clear concise key messages regarding vaccine safety controversies.

Dr. Barbara Law
Public Health Agency of Canada

Vaccine Effectiveness – Evidence of Impact

By the end of the session, participants will be able to:

- Describe the historical impact of immunization on the epidemiology of vaccine-preventable disease;
- Explain why reporting vaccine-preventable diseases contributes to knowledge about vaccine effectiveness;
- Describe how vaccine effectiveness can be measured; and
- Summarize the evidence regarding the impact of immunization programs introduced as part of the National Immunization Strategy (VZV, pneumococcal conjugate, meningococcal conjugate, and acellular pertussis vaccine for adolescents and adults).

Dr. Philippe De Wals
Institut national de santé publique du Québec

Tuesday, December 2

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

DAY-BY-DAY PROGRAM



Distinguished Lecture in Canadian Immunization: Evidence-based Decision Making for Vaccine Programs in Canada

This lecture will be given in honour of the late Dr. Bernard Duval. In addition to working with Northern Quebec Inuit communities and working as a technical advisor for the United Nations in Senegal, Dr. Duval worked in Quebec City in the control and prevention of communicable diseases since 1986. He was one of the several key people involved in the implementation of the highly successful Hepatitis B vaccination program in Quebec. Dr. Duval passed away in April 2008. Join us in honouring Dr. Duval's tremendous contributions to the immunization field during this lecture.

By the end of the session, participants will be able to:

- Describe the major categories of evidence that must be taken into consideration before introducing a new immunization program;
- Explain why and under what conditions the immunization schedules selected for an immunization program in Canada may differ from the approved ones;
- Describe the changes in the Canadian immunization environment, given the introduction of new immunization programs, and the resulting impacts on relevant decision making processes in the XXIst century; and
- Envision how vaccinologists throughout Canada may be able to rise up to the challenges of true evidence-based decision making.

Dr. Gaston De Serres
Institut national de santé publique du Québec

12:30-13:30 **BUFFET LUNCH – EXHIBIT AND POSTER VIEWING** **Osgoode Ballroom, Sheraton Hall**

12:30-13:30 **LUNCHTIME WORKSHOPS**
Refer to page 46 for details **Windsor West Grand Ballroom East**

13:30-15:00 **CONCURRENT SESSION (1 OF 7)**

- PRIMER**
- IC1**
- IC4**
- IC5**

Vaccinology: Update for Immunizers (*This session is repeated from Monday*) **Dominion Ballroom North**
Chair: Dr. Joanne Langley
National Advisory Council on Immunization

Competent immunization delivery requires both an understanding of and an ability to communicate basic principles of immunology, vaccine components and properties and population health. In this session, participants will learn the basics of the immune response to vaccines, how the type of vaccine and its components may influence the immune response, and key principles of population health relevant to immunization and to optimizing immunization coverage rates.

By the end of the session, participants will be able to:

- Explain how vaccines work using a basic knowledge of the immune system;
- Describe host and vaccine factors that influence the immune response to vaccines;
- Respond to concerns that giving too many vaccines will overwhelm the immune system;
- Compare the major advantages and disadvantages of live attenuated versus inactivated / subunit immunizing agents; and
- Explain the concept of herd immunity (also called community immunity) in non-scientific terms.



Dr. Joanne Langley
Dalhousie University

Vaccine Type and Composition: Why do I need to know?

Marina Salvadori
Children's Hospital of Western Ontario

Population Health for Immunizers: A Primer

Dr. Geneviève Petit
Université de Sherbrooke

13:30-15:00

CONCURRENT SESSION (2 OF 7)

- EMERG**
- IC1**
- IC4**

Adjuvants, the Immunologist's Little Secret

Dominion Ballroom South

Chair: Dr. Tobias Kollmann
University of British Columbia

The central role of adjuvants in vaccines is increasingly recognized. This session will provide attendees with insight into why adjuvants are necessary to provide optimal long-lived immune responses to vaccines, and how they work.

By the end of the session participants will be able to:

- Describe why adjuvants are necessary for an immune response to immunization;
- Summarize the role of adjuvants in targeting mainly the innate immune system in immunization; and
- Explain how the adjuvant-driven innate immune response to vaccines dictates quality and quantity of the long-lived, protective adaptive (T cell, B cell, Antibody) response.

Adjuvants, the Vaccinologist's Secret: Focus on Early Life Vaccine Responses

Dr. Tobias Kollmann
University of British Columbia

Adaptive Immune Response in Early Life: What Can We Learn From Cytomegalovirus Infection

Dr. Arnaud Marchant
Université Libre de Bruxelles

Novel Formulations for Early Life Vaccines

Dr. Volker Gerdts
University of Saskatchewan

13:30-15:00

CONCURRENT SESSION (3 OF 7)

- COMM**
- IC5**
- IC6**
- IC11**

Reaching Special Populations

Grand Ballroom East

Chair: Marie Adèle Davis
Canadian Paediatric Society

This session will explore communication strategies to reach three different populations: downtown Vancouver transients, remote Aboriginal communities in the North, and university/college students in Nova Scotia.

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

Tuesday, December 2

DAY-BY-DAY PROGRAM



By the end of the session, participants will:

- Explore the challenges of communicating with hard-to-reach populations;
- Examine unique communication strategies for specific communities; and
- Be able to discuss applicable strategies for reaching other unique populations.

Reaching the Transient Population in Downtown Eastside Vancouver

Dr. Reka Gustafson
Vancouver Coastal Health

Strategies to Enhance Immunization Coverage in Aboriginal Communities

Wanda White
Government of the Northwest Territories

Targeting Post-Secondary Students in Nova Scotia

Brett Loney
Department of Health Promotion and Protection

13:30-15:00

CONCURRENT SESSION (4 OF 7)

INNOV

IC12

Post-Market Schedule Optimization: Different Schedules or Just Consistent Schedules **Civic Ballroom**

Chair: Dr. Shelly McNeil
*Canadian Center for Vaccinology
Dalhousie University*

In this session, controversies in post-market immunization scheduling including harmonization of immunization schedules in Canada and alteration of approved schedules for vaccines will be debated.

At the end of the session, participants will be able to:

- Describe the advantages and disadvantages of implementing a single childhood immunization schedule in all jurisdictions in Canada; and
- Describe the rationale, challenges, advantages, and disadvantages of implementing immunization programs using schedules different than those approved by the manufacturer and regulatory agencies.

Debate 1 - All Jurisdictions in Canada Should Use a Common Childhood Immunization Schedule

Dr. Noni MacDonald
Dalhousie University

Anita Hanrahan
Capital Health

Debate 2 - Publicly-Funded Immunization Programs Should Utilize Vaccine Schedules as Approved by the Manufacturer and the Regulatory Agency

Dr. Gaston De Serres
Institut national de santé publique du Québec

Dr. Alan West
Partner, Gowling Lafleur Henderson LLP

Tuesday, December 2

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.



13:30-15:00 CONCURRENT SESSION (5 OF 7)

LEGAL
IC14

Facing the Issues: Legal, Ethical, Informed Consent - Part I

City Hall

Chair: Debra Lynkowski
Canadian Public Health Association

This session will focus on ethical and legal issues that affect the public as they make decisions to immunize. Following an overview of ethical issues in immunization, new and practical initiatives in informed consent will be presented. The final presentation will explore the arguments for vaccine injury compensation programs in Canada.

At the end of this session, participants will be able to:

- Identify the primary ethical issues in immunization in Canada;
- Describe the inherent ethical issues in obtaining informed consent for immunization, and the inherent ethical issues in the process; and
- Identify the challenges vaccine injury compensation programs face.

Overview – Ethical Issues in Canada

Dr. Monika Naus
British Columbia Centre for Disease Control

New Initiatives in Informed Consent

Lisa Jarvos
Fraser Health

Vaccine Injury Compensation Programs

Dr. Kumanan Wilson
University of Ottawa

Dr. Jenn Keelan
University of Toronto

13:30-15:00 CONCURRENT SESSION (6 OF 7)

INNOV
IC4
IC10
IC12

Impact of New Technology Advances on Immunization Provider's Practice

Essex Ballroom

Chair: Michelle M. Long
Manitoba Health and Healthy Living

Over the past 30 years, there have been major advances in vaccine development, formulation and delivery systems. This session will examine the benefits and challenges of current and near future changes in vaccine delivery systems, adjuvants and preservatives and their potential impact on immunization practice.

Tuesday, December 2

Learning Tracks

COMM Communication of Risks and Benefits	INNOV Innovation in Vaccine Delivery	PRIMER Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL Legal and Ethical Aspects of Immunization	PROMO Promotion of Immunization
FLU Influenza	NEW New Vaccines from Concept to Implementation	

By the end of this session, participants will be able to:

- Describe benefits and challenges of current and future routes of vaccine delivery;
- Describe the current state of knowledge related to current and near future adjuvants and preservatives;
- Describe current and potential practice issues related to new technology advances in immunization administration; and
- Demonstrate an understanding of the process involved and factors considered in making recommendations regarding vaccines. This will assist the provider in interpreting vaccination recommendations.

Adjuvants and Preservatives: What are They?

Carol Lajeunesse
University of British Columbia

New Technology Advances in Immunization Administration: Impact on Practice

Dr. Anna Taddio
Hospital for Sick Children

Recommendations on Vaccine Use in Canada and New Technology Advances in Vaccine Formulation and Delivery: NACI's Perspective

Dr. Bryna Warshawsky
Middlesex-London Health Unit

13:30-15:00

CONCURRENT SESSION (7 OF 7)

COMM

IC5

IC6

Improving Uptake Through Social Marketing, Education and Surveillance Grand Ballroom West/Centre

Chair: Lyne Cantin
Public Health Agency of Canada

This session will use case studies to provide insight into the process of developing strategies to improve immunization uptake at the field, regional and provincial levels.

By the end of the session, participants will be able to:

- Understand the components of the social marketing/education planning process including needs assessment, program planning, implementation and evaluation;
- Recognize the importance of understanding the target audience;
- Describe evidence-based multifaceted strategies to improve uptake;
- Identify data collection methods at different stages of the planning process in relation to budget;
- Appreciate the importance of field-testing for determining effectiveness of interventions before final implementation; and
- Understand the importance and challenges of evaluating social marketing initiatives to improve immunization uptake.

Case Study 1: Reminder System Initiatives to Improve Uptake

Sandy Phillips
Calgary Public Health Rural North

Jeanette Humphreys
Public Health Services – Saskatoon, Saskatchewan

Case Study 2: Designing Education Materials from Research to Evaluation

Linda Poirier
Vancouver Coastal Health Communicable Disease Control

Andrea Derban
British Columbia Centre for Disease Control

Case Study 3: Designing a Social Marketing Campaign from Research to Evaluation

Ian Roe
British Columbia Centre for Disease Control

15:00-16:00 HEALTH BREAK – EXHIBIT AND POSTER VIEWING **Osgoode Ballroom, Sheraton Hall**

16:00-17:30 CONCURRENT SESSION (1 OF 7)

PRIMER

IC12

The Evidence for Program Decisions: Surveillance, Epidemiology, Disease, Impact, Modeling, Economics *(This session is repeated from Monday)*

Dominion Ballroom North

Chair: Dr. Ian Gemmill
Kingston, Frontenac and Lennox & Addington Public Health

This session will review a framework for assessing vaccines for publicly-funded programs and will use two examples of practical application of the framework to enhance understanding of how program decisions are made in Canada.

By the end of the session, participants will have gained knowledge about:

- The framework that is used to assess candidate vaccines for publicly funded programs;
- How advisory committees make recommendations on vaccine programs; and
- The factors that affect the decision to initiate publicly-funded vaccine programs and the process to implement them.

A Primer on the Framework for Assessing Vaccine Programs

Dr. Philippe De Wals
Université Laval

Using Evidence to Implement a Vaccine Program Cost Effectively: The Prevnar Story

Cheryl McIntyre
British Columbia Centre for Disease Control

Changing Programs: Epidemiology & Economics: The Twinrix™ Story in Quebec

Dr. Vladimir Gilca
Direction régionale de santé publique de la Capitale nationale

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

DAY-BY-DAY PROGRAM



16:00-17:30

CONCURRENT SESSION (2 OF 7)

Oral Abstracts

Co-chairs: Dr. Julie Bettinger
British Columbia Children's Hospital - Vaccine Evaluation Centre

Dr. Gaston de Serres
Institut national de santé publique du Québec

O13 Quality-of-Life-Years (QALY) Lost During the First 90 Days After the Onset of Herpes Zoster (HZ).
Melanie Drolet
CHA - Hôpital Saint-Sacrement

O14 Pourquoi les couvertures vaccinales des 0-2 ans en Estrie sont-elles faibles?
Dr. Maryse Guay
Institut national de santé publique du Québec

O15 Induction of Broadly Reactive Mucosal and Systemic Immune Responses By a Novel HIV-1 Vaccine Cocktail Entrapped Into a Lipid Vesicle
Ali Azizi
Variation Biotechnologies Inc., University of Ottawa

O16 Facing the Pandemic Threat: Preclinical Development of Innovative Cross-Protective H5N1 Influenza Virus-Like Particles
Nathalie Landry
Medicago Inc.

O17 Impact of Changing Laboratory Diagnostics on Influenza Surveillance
Michael Garner
Public Health Agency of Canada

O18 Universal Influenza Immunization Coverage Rates in Ontario Children
Kathy Moran
York Region Community and Health Services Department

16:00-17:30

CONCURRENT SESSION (3 OF 7)

IG11

Special Populations - New Immigrants

Dominion Ballroom South

Chair: Dr. Ann Duggan
Citizenship and Immigration Canada

Newcomers to Canada have been identified by the Canadian Immunization Committee as a special population in need of attention. However, little immunity data exists about newcomers and even less data exists about their link to vaccine-preventable outbreaks. This session will review the vaccination policy of Citizenship and Immigration Canada prior to immigration; examine the differing immunity data that exists about newcomers and the link to vaccine-preventable outbreaks; and present recent recommendations for immunization of newcomers after arrival.

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.

Tuesday, December 2



By the end of the session, participants will be able to:

- Recognize when newcomers to Canada are vaccinated before arrival and when they are not;
- Distinguish the level of immunity against VPDs in newcomers relative to the host population; and
- Compare the immunization recommendations provided in the new “Clinical Preventive Care Guidelines for Immigrants” to the NACI recommendations.

Why Don't Newcomers Just Get Vaccinated Before They Come? Vaccination Policy at Citizenship and Immigration Canada

Dr. Ann Duggan
Citizenship and Immigration Canada

Population Immunity to Vaccine-Preventable Diseases of Childhood Among Foreign-born Adults in the United States

Dr. Kamran Khan
St. Michael's Hospital

Vaccine-Preventable Disease Susceptibility in Adult Immigrants and Recent Immunization Recommendations from the Canadian Collaboration for Immigrant and Refugee Health

Dr. Christina Greenaway
Jewish General Hospital

16:00-17:30

CONCURRENT SESSION (4 OF 7)

NEW

IC2

IC3

New Vaccine Programs: Measuring the Clinical and Economic Impact

Grand Ballroom East

Chair: Dr. James Kellner
University of Calgary

This session will review existing surveillance systems for vaccine-preventable diseases in Canada and other jurisdictions and the methodology for measuring the economic impact after implementation of new vaccine programs.

In this session, participants will learn about:

- Vaccine-preventable disease surveillance systems in Canada and other jurisdictions; and
- Methodology used to measure the impact of new vaccines after implementation.

Surveillance Systems for Vaccine-Preventable Diseases in Canada

Dr. James Kellner
University of Calgary

The Active Bacterial Cores Surveillance System: Using Surveillance to Understand Vaccine Impact

Dr. Matthew Moore
Centres for Disease Control and Prevention, Atlanta

Impact of New Programs After Implementation

Dr. Marc Brisson
Université Laval

Learning Tracks

COMM

Communication of Risks and Benefits

INNOV

Innovation in Vaccine Delivery

PRIMER

Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization

EMERG

Emerging Vaccine Science and its Implications for Immunization Programs

LEGAL

Legal and Ethical Aspects of Immunization

PROMO

Promotion of Immunization

FLU

Influenza

NEW

New Vaccines from Concept to Implementation

DAY-BY-DAY PROGRAM



16:00-17:30

CONCURRENT SESSION (5 OF 7)

LEGAL

IC14

Facing the Issues: Legal, Ethical, Informed Consent - Part II

Chair: Beth Halperin
Dalhousie University

This interactive panel discussion will begin with an introduction to the concept that legal, ethical and public health factors related to immunization must be viewed through a multi-focal lens and that no single perspective can be dealt with in isolation. Focusing on two different topics, panellists will explore the complex variables impacting on vaccine delivery and uptake through the lens of the health care provider, the patient, and the system with respect to ethical, legal and public health factors. The session will conclude with a summation statement from the panel and a list of suggested readings will be provided.

By the end of the session, participants will be able to:

- Describe situations in immunization practice where the law, public health and ethics intersect;
- Explain the utility of viewing immunization issues through a multi-focal lens;
- Distinguish the interplay between the concepts of equity, autonomy and public good with respect to the impact on public health; and
- Identify some of the issues where the law is clear and where it is not with respect to immunization issues.

Dr. Noni MacDonald
Dalhousie University

Dr. Jocelyn Downie
Dalhousie University

Beth Halperin
Dalhousie University

Dr. Angus Dawson
University of Toronto

16:00-17:30

CONCURRENT SESSION (6 OF 7)

NEW

IC5

IC6

IC13

Public Confidence and Its Impact on Program Planning

Essex Ballroom

Chair: Dr. Margaret Russell
Canadian Association for Immunization Research and Evaluation

In this interactive session, participants will hear about issues and trends in public confidence related to vaccines and immunization programs as well as theories and principles for dealing with them. Participants will then work in groups to apply the theory and propose strategies to improve public confidence in immunization programs.

Tuesday, December 2

By the end of the session, participants will be able to:

- Describe issues and trends in public confidence related to immunization programs and new technologies/vaccines;
- Describe principles for dealing with public concerns;
- Apply principles for dealing with public concerns; and
- Propose strategies for immunization programs to attain optimal uptake of vaccines.

Canadian Knowledge and Attitudes About Vaccines

Dr. Paul Ritvo
York University

Vaccination: Comparisons with French and US Population-Based Samples

Dr. Paul Ritvo
York University

Ontario Experience with HPV

Dr. Ian Gemmill
Kingston, Frontenac and Lennox & Addington Public Health

Coping with Anti-vaccination 2.0

Dr. Kumanan Wilson
Toronto General Hospital

16:00-17:30

CONCURRENT SESSION (7 OF 7)

IC5

Advocacy

Chair: Marie Adèle Davis
Canadian Paediatric Society

Grand Ballroom West/Centre

This session will provide practical ideas on how to advocate for vaccines at the community and federal/provincial/territorial levels as well as some examples of time-tested tools to ensure effectiveness.

By the end of the workshop participants will be able to:

- Review the role of health professionals and their organizations in advocating for public policy or funding that will improve immunization rates;
- Discussed what can be done at the community level to promote immunization; and
- Use the HPV as a recent case study to review advocacy in action.

Eve Elman
The Canadian Medical Association

Dr. Mike Dickinson
Community Paediatrician, Miramichi, New Brunswick

Dr. Vita Senikas
Society of Obstetricians and Gynaecologists of Canada

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

DAY-BY-DAY PROGRAM



Wednesday, December 3, 2008

07:00-08:30 SATELLITE SYMPOSIUM

Advances in Protection Against Pneumococcal Disease

This session has been co-developed by Canadian Paediatric Society and GlaxoSmithKline.
Please refer to the Satellite Symposia section for details.

Civic Ballroom

08:30-10:00 PLENARY VI

FLU

Pandemic Influenza: Critical Knowledge Gaps and Canadian Efforts to Bridge Them **Grand Ballroom West/Centre**

Chair: Dr. Mark Loeb
McMaster University

This plenary will focus on the knowledge gaps facing pandemic planners and will present research efforts being undertaken in Canada to address them.

By the end of the session participants will be able to:

- Describe the key data needed for pandemic planning;
- Explain how research during the inter-pandemic period can inform pandemic preparedness; and
- Describe the breadth of Canadian pandemic research efforts.

Knowledge Gaps for Pandemic Planners

Dr. Bonnie Henry
British Columbia Centre for Disease Control

Overview of the Canadian Institutes of Health Research Funding Program

Carol Richardson
University of Western Ontario

Evaluation of Urban Triage Centers

Dr. David Johnson
Capital Health

Pandemic Ethics Research

Dr. Nuala Kenny
Dalhousie University

10:00-10:30 HEALTH BREAK – POSTER VIEWING

Osgoode Ballroom

Wednesday, December 3

Immunization Competencies for Health Professionals

Go to page 3 for the Immunization Competency definitions.



10:30-12:20

PLENARY VII

IC13

The Bottom Line: Hot Topics & Ask the Experts

Grand Ballroom West/Centre

Chair: Dr. Barbara Law
Public Health Agency of Canada

Dr. Joanne Langley
National Advisory Council on Immunization

This plenary session will cover a variety of issues related to the basis of immunization; introduction and use of vaccines in publicly funded programs in Canada (programmatic issues); and issues related to immunization practices.

The session consists of two components, presented by a panel of experts in the field of immunization and vaccines:

1. Hot Topics: a series of presentations on “hot off the press” newly-emerging issues or information on vaccines and immunization; and
2. Ask the Experts: a panel discussion of responses to questions that have been submitted by Conference participants.

Dr. Ian Gemmill
Kingston, Frontenac, Lennon and Addington Public Health

Dr. Allison McGeer
Mount Sinai Hospital

Dr. Simon Dobson
British Columbia's Children's Hospital

Ms. Anita Hanrahan
Capital Health

Dr. Jamie Pringle
Vancouver Coastal Health

Through this session, participants will improve their ability to:

- Discuss current issues, related to vaccines and immunization that have been identified by immunization providers in the field;
- Discuss the “best practices” to address these issues; and
- Discuss emerging issues, in the areas of vaccines and immunization.

12:20-12:30

CLOSING REMARKS

Wednesday, December 3

Learning Tracks

COMM	Communication of Risks and Benefits	INNOV	Innovation in Vaccine Delivery	PRIMER	Primers: Evidence-Based Clinical Practice and Program Decisions for Immunization
EMERG	Emerging Vaccine Science and its Implications for Immunization Programs	LEGAL	Legal and Ethical Aspects of Immunization	PROMO	Promotion of Immunization
FLU	Influenza	NEW	New Vaccines from Concept to Implementation		

LUNCHTIME WORKSHOPS



Monday, December 1

12:30-13:30

LUNCHTIME WORKSHOP

Windsor West

Plain Language

Who are you writing for? Is your audience made up of government or public health officials, members of the public or colleagues? Whether your writing appears in reports, public information materials or on web sites, its effectiveness is measured by how well your intended audience understands your message and whether they act on it. This workshop will allow you to learn and practice five plain writing tips. Plain writing helps you communicate with greater confidence and clarity and will benefit any audience you write for.

Debra Isabel Huron
Consultant

Limited space available – pre-registration required.



Tuesday, December 2

12:30-13:30

LUNCHTIME WORKSHOP

Writing for Journals

Windsor West

This one hour workshop will give participants tips and strategies to use when writing for peer-reviewed journals.

Dr. Noni MacDonald
Dalhousie University

Limited space available – pre-registration required.

12:30-13:30

LUNCHTIME WORKSHOP

Cold Chain Strategies "Tips and Tricks of the Trade"

Grand Ballroom East

Chair: Céline Couturier
New Brunswick Department of Health

This workshop will cover three topics pertaining to the importance of maintaining the cold chain for successful vaccine programs. Best Practice guidelines on "How to Pack a Vaccine Cooler Bag" to ensure the minimum requirements of the cold chain are maintained during large immunization clinics will be reviewed by Toronto Public Health. In the second presentation, tools and processes needed to monitor and maintain the cold chain during vaccine transportation will be discussed. The final presentation will explore strategies used to liaise with immunizing physicians to increase their awareness of the cold chain in order to maintain vaccine effectiveness.

How to Pack a Vaccine Bag – Maintenance of the Cold Chain During Mass Immunization Clinics

Karie Robinson
Toronto Public Health

Sanjay Thuraisamy
Toronto Public Health

Vaccine Transportation: Tools to Monitor and Maintain the Cold Chain During Transportation

Leslie Doan
Red Deer Johnstone Crossing Community Health Centre

Strategies to Get Physicians Engaged and Pay More Attention to the Cold Chain

Marion Guenther
Vancouver Coastal Health

Limited space available – pre-registration required.



POSTERS

Osgoode Ballroom

Sunday, November 30 to Monday, December 1

Authors will be present during the daily scheduled breaks.

P01 TRIVALENT INFLUENZA VACCINE EFFECTIVENESS AGAINST INFANT/TODDLER HOSPITALIZATION DURING THREE CANADIAN WINTERS: A REPORT FROM THE IMMUNIZATION MONITORING PROGRAM - ACTIVE (IMPACT)

G De Serres, DL Moore, W Vaudry, DW Scheifele, SA Halperin, P Déry, A McGeer, J Embree, MH Lebel, N Le Saux, BJ Law, Y Li, DM Skowronski
Québec, Québec

P02 SUSCEPTIBILITY TO MEASLES, MUMPS AND RUBELLA IN REFUGEES AND IMMIGRANTS IN TORONTO

M Rashid, M Rashid, YB Shakya, N Sadiq, C Foo
Toronto, Ontario

P03 VACCINE PREVENTABLE DISEASES AND MULTIPLE ORGAN DYSFUNCTION SYNDROME IN A PICU IN CHINA

N Macdonald, QL Zhang, CM Wan
Halifax, Nova Scotia

P04 MMR VACCINE REACTIONS: THE ALBERTA EXPERIENCE

C Dribnenki, L McDonald, EM Sartison
Edmonton, Alberta

P05 CELLULAR IMMUNITY TO DIPHTHERIA AND TETANUS TOXOIDS AND ACCELLULAR PERTUSSIS VACCINE ANTIGENS IS PROMINENT IN 4-5 YEAR OLD CHILDREN

D Scheifele, J Ochnio, SA Halperin, J Wang
Vancouver, British Columbia

P06 AN INNOVATIVE APPROACH TO FOSTER HPV VACCINE RESEARCH AND EDUCATION IN CANADA

S Dobson, B Duval, M Fung Kee Fung, C Sauvageau, P De Wals, MH Mayrand, E Franco
Vancouver, British Columbia

P07 OUTCOMES ASSOCIATED WITH SPLENECTOMY(S) IN NOVA SCOTIA(NS): 1990-2002

J Langley, L Dodds, D Fell, GR Langley
Halifax, Nova Scotia

P08 VACCINATED CHILDREN AMONG HOSPITALIZED MENINGOCOCCAL CASES ACROSS CANADA, IMPACT 2002-2006

J Bettinger, N Le Saux, DW Scheifele, SA Halperin, W Vaudry, R Tsang
Vancouver, British Columbia

P09 ECONOMIC IMPACT OF INFLUENZA VACCINATION OF PREGNANT WOMEN (PW) IN NOVA SCOTIA (NS): NET COST, COST-EFFECTIVENESS AND BUDGET IMPACT

S McNeil, C Skedgel, J Scott, N MacDonald, JM Langley
Halifax, Nova Scotia

P11 NEW VACCINES PRIORITY RATING - DATA FROM A NURSES SURVEY

V Gilca, N Boulianne, E Dube, M Ouakki, C Sauvageau
Québec, Québec

P13 EFFECTIVENESS OF SEROGROUP C MENINGOCOCCAL CONJUGATE

VACCINE: A 5-YEAR FOLLOW-UP IN Québec, CANADA
P De Wals, G Deceuninck, N Boulianne, G de Serres
Québec, Québec

P14 WHAT NURSES THINK ABOUT OTITIS MEDIA PREVENTION BY VACCINATION?

V Gilca, PH De Wals, N Boulianne, E Dube, C Sauvageau
Québec, Québec

P15 DEVELOPING IMMUNIZATION CHAMPIONS: CAN KNOWLEDGE AND POSITIVE ATTITUDES & BEHAVIOURS BE ACHIEVED AND MAINTAINED OVER TIME.

A Henteleff, A Henteleff, L Connors, S McNeil
Winnipeg, Manitoba

P16 A RESPIRATORY SYNCYTIAL AND OTHER VIRUS SURVEILLANCE SYSTEM TO IMPROVE PASSIVE IMMUNIZATION NS 2005-2008

J Langley, A Al-Azem
Halifax, Nova Scotia

P17 NEW HPLC METHOD FOR ANALYSIS AND QUALITY CONTROL OF PANDEMIC INFLUENZA VACCINES

J Amell, J Wang, W Lim, K Anandavel, H MacDonald-Piquard, F Bouthillier, H Rode
Ottawa, Ontario

P20 IMMUNIZATION OF NEONATES: GREATER PROTECTION, STRONGER AND BROADER IMMUNE RESPONSES AND A UNIQUE MEMORY T CELL PROFILE

B Reikie, K Smolen, DI Loeffler, DP Blimkie, TR Kollmann
Vancouver, British Columbia

P21 KNOWLEDGE, ATTITUDES AND BELIEFS OF CANADIAN PARENTS ABOUT ACUTE OTITIS MEDIA AND ITS PREVENTION BY IMMUNIZATION: RESULTS OF A TELEPHONE SURVEY

E Dubé, P De Wals, V Gilca, N Boulianne, M Ouakki
Québec, Québec

P22 PLANNING FOR UPTAKE OF VACCINE AMONG HEALTH CARE WORKERS DURING THE NEXT INFLUENZA PANDEMIC

T Appleyard
Toronto, Ontario

P23 VACCINATION COVERAGE OF HEPATITIS B AMONG RESIDENTS OF A SQUATTER SETTLEMENT IN KARACHI, PAKISTAN

M Aslam, A Mubashir, T Tahir, MR Ali
Karachi, Sindh

P24 AUTOMATED IDENTIFICATION OF VACCINE PRODUCTS (AIVP) PROGRESS REPORT: PROPOSED IMPLEMENTATION STRATEGY FOR BAR CODING VACCINE PRODUCTS

AJ Diniz, T Harris, L Lamarche
Ottawa, Ontario



P25 PUBLIC HEALTH ON CALL

V Beynon
 High Prairie, Alberta

P26 PEACE COUNTRY HEALTH INNOVATIONS IN IMMUNIZATION (PCHIS)

V Beynon
 High Prairie, Alberta

P27 Québec NURSES' OPINIONS ABOUT ROUTINELY RECOMMENDED CHILDHOOD VACCINES

N Boulianne, V Gilca, È Dubé, F Lavoie
 Québec, Québec

P29 FEASIBILITY AND IMMUNOGENICITY OF INTRA-DERMAL VACCINATION AGAINST RABIES IN Québec

Y-G Bui, F Milord, E Cambron-Goulet, AM Clouâtre, E Levac, F Lord
 Longueuil, Québec

P30 CAN WE NOW CHANGE OUR POLICY OF TETANUS PROPHYLAXIS THANKS TO A BEDSIDE IMMUNOCHROMATOGRAPHIC TEST FOR THE DETECTION OF ANTI-TETANUS ANTIBODIES?

JC Cavenaile, Z Vafa, J Herrero Garcia
 Brussels

P31 APPORT CLINIQUE DU TETANOS QUICK STICK™ DANS LA PREVENTION DU TETANOS DANS UN SERVICE D'URGENCES

JC Cavenaile, J Herrero Garcia
 Bruxelles

P32 HUMAN PAPILLOMAVIRUS VACCINE ACCEPTABILITY: A TARGETED LITERATURE REVIEW OF HEALTH CARE PROFESSIONALS, PARENTS, AND YOUNG ADULTS

V Delisle, AK Krawczyk, ZR Rosberger
 Blainville, Québec

P33 THE 2007/08 HPV VACCINATION PROGRAM FOR GRADE 8 FEMALES IN TORONTO: PROCESS, CHALLENGES AND PROGRAM RECOMMENDATIONS

V Dubey, A Mathur, J Cameron, J Kaashoek
 Toronto, Ontario

P34 PREDICTORS OF UPTAKE OF UNIVERSAL INFLUENZA IMMUNIZATION IN GRADE 1 AND 2 SCHOOLCHILDREN IN TORONTO.

R Foty, SDD Dell, AG Guttman, JK Kwong, SM Maaten, DM Manuel, DMS Stieb
 Toronto, Ontario

P35 DELAYED IMMUNIZATION MONITORING SYSTEM FOR PRESCHOOL CHILDREN IN CAPITAL HEALTH

R Golonka, RP Golonka
 Edmonton, Alberta

P36 INNOVATION IN IMMUNIZATION: ENHANCING ACCESS FOR UNDER-IMMUNIZED CHILDREN IN CAPITAL HEALTH

R Golonka, RP Golonka
 Edmonton, Alberta

P37 EFFECTIVENESS OF A VACCINATION REMINDER SYSTEM IN TORONTO, CANADA

E Gournis, O Kadri, M Finkelstein, L Persaud, A Mathur, E Gournis, V Dubey
 Toronto, Ontario

P38 GET VACCINATED WITH GERRI THE GIRAFFE: PROMOTING CHILDHOOD IMMUNIZATION AND VACCINATION REPORTING.

D Grakist
 Ottawa, Ontario

P39 DO SIMULTANEOUS INJECTIONS REDUCE DISTRESS AND PAIN IN INFANTS RECEIVING MULTIPLE INJECTIONS?

D Hanson, W Hall, R Bhagat, L Mills, N Slomba, M Hernandez, S Au
 Vancouver, British Columbia

P41 IMMUNIZING CHILDREN WHO FEAR NEEDLES: KEY ISSUES FOR NURSE IMMUNIZERS

M Ives
 Chilliwack, British Columbia

P42 ECONOMIC ANALYSIS OF A PUBLIC PROGRAM FOR PNEUMOCOCCAL VACCINE IMMUNIZATION

P Jacobs, A Chuck, T Nguyen, A Hanrahan, A Ohinmaa, J Loewen, L Mashinter, W Vaudry, J Kellner
 Edmonton, Alberta

P43 DON'T BREAK THE CHAIN: EVALUATING COLD-CHAIN THERMOMETER RELIABILITY

R Kavanagh, J Futcher, J Cunningham, D Williams
 Smiths Falls, Ontario

P44 VACCINATION PRACTICES AND FACTORS INFLUENCING EXPANDED PROGRAMME OF IMMUNIZATION IN THE RURAL AND URBAN SET UP OF PESHAWAR

H Khan, A Hameed, N Jan
 Pakistan

P45 CORRELATES OF HUMAN PAPILLOMAVIRUS ACCEPTABILITY: A PILOT STUDY OF UNIVERSITY STUDENTS IN MONTREAL

A Krawczyk, V Delisle, Z Rosberger
 Montréal, Québec

P46 USE OF A TOPICAL ANAESTHETIC FOR PAIN REDUCTION IN ADOLESCENT HPV IMMUNIZATION

C LaJeunesse, S Fan, A Kallos, J Bettinger, K Marty
 Vancouver, British Columbia

P47 A NOVEL APPLICATION OF SURVEILLANCE ALGORITHMS IN CHILDHOOD IMMUNIZATION PROGRAM MONITORING

L McDonald, N Yiannakoulis, L Svenson
 Edmonton, Alberta

P48 PROJET VIP: QUALITÉ DES PRATIQUES DE VACCINATION PRÉ-POST, UNE FORMATION INTERACTIVE STANDARDISÉE

C Larue, M.L M Letellier, M Julien, G Petit, L Gauvin, C Guimond
 Montréal, Québec



P49 INTERIM EVALUATION OF THE NATIONAL IMMUNIZATION STRATEGY

(NIS) 2003-2007

D Taylor, S Jain, C Pinset, L Belzak, M Farhangmehr
 Ottawa, Ontario

P50 EFFECT OF SCHOOL-BASED INFLUENZA IMMUNIZATION CLINICS ON HEALTH CARE UTILIZATION

H Ge, JC Kwong, L Rosella, A Guttman
 Toronto, Ontario

P51 EXAMINING REASONS FOR INCOMPLETE IMMUNIZATION STATUS AMONG DAY CARE CHILDREN

J Fediurek, LM MacDonald, AS Stevens, JT Tober, MC Costie, JG Genua, RH Hesch, KP Paddock
 Brantford, Ontario

P52 MODELLING THE CLINICAL CONSEQUENCES OF INTRODUCING AN INTRADERMAL INFLUENZA VACCINE AMONG ELDERLY IN ONTARIO

S Aballéa, J Roiz, JC Kwong, P Murray, R Van Exan
 Uxbridge, Middlesex

P53 THE UTILIZATION OF AND SATISFACTION WITH PEDIATRIC PREVENTIVE HEALTH SERVICES IN SAUDI ARABIA: IMPLICATIONS FOR PUBLIC POLICY

S Alghanim, MR Alyemeni, AO Albarrak
 Riyadh, Riyadh

P54 NEEDLE STICK INJURIES AMONG HEALTH CARE WORKERS IN TERTIARY CARE HOSPITALS OF KARACHI

M Aslam, T Taj, A Ali
 Karachi, Pakistan

P55 COST EFFECTIVENESS OF A PUBLICLY FUNDED HEPATITIS B VACCINATION PROGRAM FOR BLOOD DONORS IN BRITISH COLUMBIA

M Bigham, ST Waters, M Bigham
 Vancouver, British Columbia

P56 IMPACT OF CHANGING THE FOUR DOSE CHILDHOOD PNEUMOCOCCAL

A Campbell, R Findlater, S Hudson, J Irvine, M Nsungu, GB Horsman, PN Levett, K Whitehawk, R Tuchscherer, B Rushowick
 Regina, Saskatchewan

P57 PROVINCIAL PROGRAM FOR RSV IMMUNOPROPHYLAXIS FOR INFANTS BORN 33-35 WEEKS GESTATIONAL AGE

A Chiu, R Paulley, S Anderson
 Winnipeg, Manitoba

P58 MANITOBA RSV IMMUNOPROPHYLAXIS PROGRAM: INCREASE IN ENROLMENT WITH INCREASE IN ELIGIBILITY CRITERIA

A Chiu, R Paulley, S Anderson
 Winnipeg, Manitoba

P59 MEASLES SUSCEPTIBILITY TESTING IN ONTARIO

N Crowcroft, J Maregem, T Kozlowski, L Coloquio
 Toronto, Ontario

P60 TWO-YEAR OLD IMMUNIZATION COVERAGE RATES IN THE REGINA QU'APPELLE HEALTH REGION BY NEIGHBORHOOD AND RURAL COMMUNITY

T Diener, Z Abbas, M Granger

P61 TRAVEL IMMUNIZATION ACCEPTANCE RATES AMONG IMMIGRANTS VISITING FRIENDS OR RELATIVES IN THEIR HOME COUNTRIES AS COMPARED TO BUSINESS AND THOSE TRAVELLING FOR WORK/STUDY ABROAD

T Diener, Z Abbas, D Martin
 Regina, Saskatchewan

P62 CONSEQUENCES OF ACUTE OTITIS MEDIA IN CANADA: PRELIMINARY RESULTS OF A TELEPHONE SURVEY

Eve Dubé, P De Wals, V Gilca, N Boulianne, M Ouakki
 Québec, Québec

P63 REPOSE IMMUNE A INFLUENZA

J Eslahpazir, BW Brian Ward
 Montréal, Québec

P64 EVALUATION OF THE THREE-DOSE SCHEDULE OF CONJUGATE PNEUMOCOCCAL VACCINE IN BRITISH COLUMBIA

M Anderson, D Patrick, ST David, M Li, L MacDougall, C McIntyre, R Wong, L Hoang, M Naus
 Vancouver, British Columbia

P65 REPORTED CASES OF THROMBOCYTOPENIA FOLLOWING IMMUNIZATION IN CANADA JANUARY 1997 TO MAY 2008

H Anyoti
 Ottawa, Ontario

P66 EMERGENCE OF OSELTAMIVIR RESISTANCE AMONG INFLUENZA A/ H1N1 VIRUSES DURING THE 2007-2008 SEASON

S Aziz, S Desai, T Booth
 Ottawa, Ontario

P67 A UNIQUE CANADIAN MODEL OF INVESTIGATORS & INDUSTRY RESEARCH SPONSORS WORKING TOGETHER TO IMPROVE VACCINE RESEARCH CULTURE & OPPORTUNITIES

G Bjornson, D Scheifele, B Duval, SA Halperin, B Ward
 Vancouver, British Columbia

P68 IDENTIFICATION OF CHRONIC HEPATITIS B AND HEPATITIS C CO-INFECTION IN BRITISH COLUMBIA FROM 1991 TO 2007

J Buxton, JA Buxton, A Yu
 Vancouver, British Columbia

P69 IDENTIFICATION OF ACUTE VACCINE-PREVENTABLE HEPATITIS IN INDIVIDUALS WITH CHRONIC HEPATITIS IN BRITISH COLUMBIA FROM 1991 TO 2007

J Buxton, JA Buxton, A Yu
 Vancouver, British Columbia



P70 INFLUENZA VACCINE EFFECTIVENESS IN COMMUNITY-DWELLING ELDERLY IN ONTARIO
 M Campitelli, JC Kwong, LC Rosella, TA Stukel
 Brampton, Ontario

P71 USING PASSIVE ADVERSE EVENTS SURVEILLANCE DATA TO RESPOND TO INQUIRIES ABOUT VACCINE SAFETY, British Columbia
 S David, ST David, M Anderson, M Naus, C McIntyre, R Wong, W Tang
 Vancouver, British Columbia

P72 THE EPIDEMIOLOGY OF INVASIVE MENINGOCOCCAL DISEASE IN NOVA SCOTIA - ARE WE SUCCESSFUL IN PREVENTION AND CONTROL?
 A Coombs, S Sarwal, K McGill
 Halifax, Nova Scotia

P73 INFLUENZA SURVEILLANCE IN CANADA: 2007-2008 SEASON
 FR Domingo, S Aziz, B Winchester, Y Li, W Vaudry, J Bettinger, L Pelletier, J Spika
 Ottawa, Ontario

P74 2006 & 2006 ADULT NATIONAL IMMUNIZATION COVERAGE SURVEY
 A-M Frescura, L Belzak
 Ottawa, Ontario

P75 RESULTS FROM THE 2006 NATIONAL CHILDHOOD IMMUNIZATION COVERAGE SURVEY
 A-M Frescura, L Belzak
 Ottawa, Ontario

P76 IMMUNOGENICITY OF A NOVEL INTRADERMAL INFLUENZA VACCINE IN ADULTS AGED LESS THAN 60 YEARS: RANDOMISED CONTROLLED PHASE 3 TRIAL RESULTS
 M Saville, R Arnou, A Ambrozaitis, P Eavis, JR De Juanes Pardo, L Barreto
 France

POSTERS

Osgoode Ballroom

Tuesday, December 2 to Wednesday, December 3

Authors will be present during the daily scheduled breaks.

P77 GUIDELINES FOR THE PREVENTION AND CONTROL OF MUMPS OUTBREAKS IN CANADA
 M Garner, A Dalloo, T Lipskie
 Ottawa, Ontario

P78 THE PAIN BURDEN IN THE FIRST 90 DAYS AFTER THE ONSET OF HERPES ZOSTER (HZ).
 M Drolet, RW Johnson, MJ Levin, MN Oxman, DM Patrick, KE Schmadler, JA Mansi
 Québec, Québec

P79 ECONOMIC IMPACT OF INFLUENZA VACCINATION OF PREGNANT WOMEN (PW) IN NOVA SCOTIA (NS): NET COST, COST-EFFECTIVENESS AND BUDGET IMPACT
 B Halperin, J Scott, N MacDonald, J Langley, S McNeil
 Halifax, Nova Scotia

P81 ENSURING OUR POLIO-FREE STATUS: ACTIVE ACUTE FLACCID PARALYSIS SURVEILLANCE IN CANADA
 M Garner, J Macey, D Grenier
 Ottawa, Ontario

P82 HEPATITIS A AND TRAVEL AMONGST NOVA SCOTIA POST-SECONDARY STUDENTS: EVIDENCE FOR A TARGETED VS. UNIVERSAL IMMUNIZATION STRATEGY
 S Halperin, KM Matheson, BA Halperin, S McNeil, D MacKinnon-Cameron, SA Halperin
 Halifax, Nova Scotia

P83 PERTUSSIS IMMUNIZATION IN HEALTHCARE WORKERS: KNOWLEDGE, ATTITUDES AND BEHAVIOUR
 S Halperin, K Top, BA Halperin, D MacKinnon-Cameron, SA Halperin
 Halifax, Nova Scotia

P84 TRANSMISSION DE L'INFORMATION PAR VIDÉO LORS DU CONSENTEMENT À LA VACCINATION INFLUENZA OU ZONA
 M Guay, V Beaudry, J Doyon-Olivier, M Godmaire, LP Poulin, S Ramsay, AM Clouâtre
 Longueuil, Québec

P85 VARICELLA CATCH-UP PROGRAM FOR TODDLERS AND PRESCHOOLERS, BRITISH COLUMBIA: IMPACT ON VACCINE UPTAKE
 M Naus, M Chong, S David, C McIntyre
 Vancouver, British Columbia

P86 MOTHERS' BELIEFS ABOUT ANALGESIA DURING CHILDHOOD IMMUNIZATION: A QUALITATIVE STUDY.
 A Taddio, A Taddio, H Boon, J Stinson, V Shah
 Toronto, Ontario



P87 IMMUNIZATION EDUCATION AND RESOURCE DEVELOPMENT: VANCOUVER COASTAL HEALTH'S EXPERIENCE WITH FIELD-TESTING – AN IMPORTANT STEP IN THE PROCESS
T Morgana, K Zinser, M Smythe, L Poirier, S Weatherill
Vancouver, British Columbia

P88 LABORATORY CHARACTERIZATION OF INVASIVE HAEMOPHILUS INFLUENZAE ISOLATES COLLECTED FROM IMPACT CENTRES FROM JANUARY 2007 TO JANUARY 2008
M Sill, B Tan, D Scheifele, D Law, W Vaudry, S Halperin, B Law, R Tsang
Winnipeg, Manitoba

P89 GENETIC ANALYSIS OF INVASIVE NEISSERIA MENINGITIDIS STRAINS IN CANADA MONITORED BY THE IMPACT PROGRAM FROM 2002 TO 2006
R Tsang, J Bettinger, S Wootton, D Scheifele, N Le Saux, S Halperin, W Vaudry, J Zhou, M Cameron, D Law, IMPACT Investigators
Winnipeg, Manitoba

P90 COMPARATIVE STUDY OF THE NEUTRALIZATION TEMPERATURES USED IN THE POTENCY ASSAY FOR THE MEASLES AND MUMPS COMPONENTS OF COMBINATION VACCINES
KH Yeung, D Lacombe, A Dallaire, B Moffitt, M Reed, A Bliu, KH Yeung, A Rinfret
Ottawa, Ontario

P91 IMMUNOGENICITY AND SAFETY ANALYSIS OF AN INACTIVATED PROTOLLIN-BASED NASAL VACCINE TO MUMPS VIRUS
K Young, S Nzula, C Rodeheffer-Petrie, A Brewer, D Burt, BJ Ward
Montréal, Québec

P92 IMPACT OF KNOWLEDGE, ATTITUDES AND BARRIERS TO IMMUNIZATION ON UPTAKE OF VARICELLA VACCINE IN TODDLERS FOLLOWING TARGETED MAIL REMINDERS, British Columbia
S David, ST David, M Naus, M Chong, C McIntyre
Vancouver, British Columbia

P93 IMMUNIZATION COVERAGE AT TWO YEARS OF AGE, British Columbia, 2004-2007
S David, ST David, M Naus, R Wong, M Anderson, C McIntyre, M Chong
Vancouver, British Columbia

P94 EXPLORING BARRIERS TO IMMUNIZATION USING A POPULATION HEALTH APPROACH
S MacDonald, CV Newburn-Cook, M Allen
Edmonton, Alberta

P95 ASSESSING BARRIERS TO IMMUNIZATION: MINIMIZING NON-RESPONSE BIAS IN A POSTAL SURVEY
S MacDonald, CV Newburn-Cook
Edmonton, Alberta

P96 SKILLS ONLINE: DEVELOPING A PUBLIC HEALTH WORKFORCE FOR THE 21ST CENTURY
K MacDougall, J Lowe, C Betker
Vancouver, British Columbia

P97 GEOGRAPHIC AND DEMOGRAPHIC FACTORS ASSOCIATED WITH NON-IMMUNIZATION IN ALBERTA
L McDonald, N Yianakoulis, L Svenson
Edmonton, Alberta

P98 ALBERTA IMMUNIZATION COVERAGE RATE CALCULATION: USING REGISTRY DATA FOR MORE PRECISE MEASURES
L McDonald, N Yianakoulis, L Svenson, J Svenson
Edmonton, Alberta

P99 INFLUENZA VACCINATION CAMPAIGNS FOR HEALTHCARE ORGANIZATION STAFF: A SYSTEMATIC REVIEW
P-P Lam, DM Pierrynowski Gallant, LW Chambers, AE McCarthy
Ottawa, Ontario

P100 PERSONAL VS. PROFESSIONAL: CHIROPRACTORS & PATIENT REFERRAL FOR IMMUNIZATION
E Medd, ML Russell
Calgary, Alberta

P101 FIRST NATIONS AND INUIT HEALTH – MANITOBA REGION: IMMUNIZATION ENHANCEMENT PROJECT
B Nichol, K Shafto
Winnipeg, Manitoba

P103 HPV IMPLEMENTATION: READY, SET, GO...
C OKeefe, MS Butler
St. John's, Newfoundland

P104 THE STATE OF ADULT VACCINATION IN ONTARIO: A FOCUSED MULTISECTORAL CONSULTATION
B Pakes, S Wilson, A McGeer
Toronto, Ontario

P105 INTEGRATING CORE COMPETENCIES FOR IMMUNIZATION PROVIDERS INTO NURSING CURRICULA: AN ATLANTIC REGION PERSPECTIVE
D Pierrynowski Gallant, SA McNeil, DM Pierrynowski Gallant, SL Bowman, L Pelly
Antigonish, Nova Scotia

P106 HEPATITIS B CONTROL FOR CHINESE IMMIGRANTS IN CANADA: A SYSTEMATIC REVIEW OF OVERCOMING BARRIERS INVOLVED IN HEPATITIS B TESTING AND VACCINATION
S Rouhani, C O'leary, Z Hong, J Wu, HX Wu
Ottawa, Ontario

P108 INTEGRATED APPROACH TO INFLUENZA IMMUNIZATION
M Sanderson
Melita, Manitoba

P109 «YOUR CHOICE ...THEIR FUTURE»
M Schepers, L Stanford, MA Holmes
Barrie, Ontario



P110 IMMUNIZATION E-DOCUMENTATION: LESSONS FROM THE FIELD
 D Shaw
 Lethbridge, Alberta

P111 USING UNIT CHAMPIONS TO PROMOTE VACCINE UPTAKE
 J Slaunwhite, SM Smith, MT Fleming, R Strang, C Lockhart
 Halifax, Nova Scotia

P112 ATTITUDES AND BELIEFS OF ACUTE HEALTH CARE WORKERS TOWARDS INFLUENZA VACCINATION
 V Sunil, E Cheuk, AM Holt, L McCarey, D Dingman, AL Noseworthy
 Port Hope, Ontario

P113 LOVE THEM, PROTECT THEM, IMMUNIZE THEM: IMMUNIZATION AWARENESS CAMPAIGN
 K Sweiger, J Haase, K Whitehouse, L White, ML Barron, C Marshall, C Coburn
 Owen Sound, Ontario

P114 ESTIMATES OF CHRONIC HEPATITIS B INFECTION IN CANADA
 H-X Wu, A Dudani, Q Li, A Andonov, J Wu
 Ottawa, Ontario

P115 SAFETY SYRINGES: HAVE PUBLIC HEALTH NURSES BEEN OVERLOOKED?
 M Yetman, G Butler, D Moralejo, C O'Keefe, H Dyson, T Bussey
 St. John's, Newfoundland

P116 PAEDIATRIC ESTIMATES OF RSV- AND INFLUENZA-ATTRIBUTABLE HOSPITALIZATION VARY BY STATISTICAL METHOD AND REQUIRE VALIDATION
 R Gilca, G De Serres, DL Buckeridge, DM Skowronski, G Boivin
 Québec, Québec

P117 IMMUNIZATION COVERAGE AND SCHOOL SUSPENSIONS BY NEIGHBOURHOOD IN TORONTO
 E Gournis, E Kefalas, E Gournis, V Duvey, J Cameron, L Persaud, B Yaffe
 Toronto, Ontario

P118 THE ECONOMIC BURDEN OF THE NOVA SCOTIA MUMPS OUTBREAK
 A Janes, RS Research supervisor, SS Thesis reader
 Deline, Northwest Territories

P119 THE COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS DNA TESTING FOR CERVICAL CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE
 J Kingston-Riechers
 Edmonton, Alberta

P120 THE EFFECT OF SCHOOL-BASED INFLUENZA IMMUNIZATION CLINICS ON VACCINATION RATES
 J Kwong, LC Rosella, H Johansen, MK Moran, S Maaten, A Guttman,
 D Northrup
 Toronto, Ontario

P121 THE EFFECT OF UNIVERSAL INFLUENZA IMMUNIZATION ON ANTIBIOTIC PRESCRIPTIONS
 J Kwong, S Maaten, REG Upshur, D Patrick, F Marra
 Toronto, Ontario

P122 STRENGTHENING PUBLIC HEALTH PRACTICE - CORE COMPETENCIES FOR PUBLIC HEALTH IN CANADA: RELEASE 1.0
 K MacDougall, C Betker, J Lowe
 Vancouver, British Columbia

P123 VACCINATION STRATEGIES FOR HEPATITIS B: IS THERE STILL CONTROVERSY?
 C Mackie, DM Patrick, JA Buxton, S Tadwalkar
 Hamilton, Ontario

P124 LABORATORY DIAGNOSIS AND SURVEILLANCE OF PERTUSSIS IN CANADA
 I Martin, M Sill, F Jamieson, S Richardson, S Halperin, R Tsang
 Winnipeg, Manitoba

P125 METHODOLOGICAL ISSUES IN SURVEILLANCE OF INFLUENZA VACCINATION AMONG YOUNG CHILDREN
 E Medd, ML Russell
 Calgary, Alberta

P126 A COMPARISON OF CHILDHOOD IMMUNIZATION COVERAGE IN CANADA AND THE UNITED STATES
 S Romain, MA Schillaci
 Whitby, Ontario

P128 THE COST-EFFECTIVENESS OF ONTARIO'S UNIVERSAL INFLUENZA IMMUNIZATION PROGRAM
 B Sander, JC Kwong, CT Bauch, A Maetzel, AJ McGeer, JM Raboud, MD Krahn
 Toronto, Ontario

P129 THE CANADIAN HIV VACCINE INITIATIVE
 V Sarazin
 Ottawa, Ontario

P130 DIX ANS DE SUIVI DE REVACCINATION SUITE A DES MANIFESTATIONS POST-VACCINALES
 J-L Grenier, E Toth, S Giroux, S Ménard, R Roussel, G De Serres, M Landry,
 M Tremblay
 St-Jerome, Québec

P131 PREDICTING THE IMPACT OF HUMAN PAPILLOMAVIRUS VACCINATION ON JUVENILE ONSET RECURRENT RESPIRATORY PAPILLOMATOSIS USING MATHEMATICAL MODELING
 M Hawkes, P Campisi
 Toronto, Ontario

P132 A NATIONWIDE SURVEY OF PAST HEPATITIS A INFECTIONS AMONG CANADIAN ADULTS
 C LaJeunesse, J Ochnio, D Scheifele, B Duval, G De Serres, V Gilca, M Ho,
 R Milner, C LaJeunesse
 Vancouver, British Columbia



P133 HEPATITIS A VACCINE USE BY CANADIAN TRAVELERS IS INADEQUATE: RESULTS OF A NATIONWIDE SURVEY

C LaJeunesse, J Ochnio, D Scheifele, B Duval, G De Serres, V Gilca, M Ho, R Milner, C LaJeunesse
Vancouver, British Columbia

P134 IMPROVED REAL-TIME PCR DETECTION SCHEME WHICH TARGETS THE BEXA CAPSULE GENE OF HAEMOPHILUS INFLUENZAE FOR ALL TYPEABLE STRAINS.

D Law, J Zhou, R Tsang
Winnipeg, Manitoba

P136 SAFETY AND IMMUNOGENICITY OF ADULT FORMULATION TDAP VACCINE FOLLOWING BLOOD AND MARROW TRANSPLANTATION (BMT) IN ADULTS

M MacFarlane Conrad, S Couban, S Halperin, J Edwards, SA McNeil
Halifax, Nova Scotia

P137 EAST MEETS WEST: THE MUMPS EXPERIENCE IN BRITISH COLUMBIA

A Maureen, M Naus, G Arsenault, E Brodtkin, M Petric, L Peters, N Cerillo
Vancouver, British Columbia

P138 HEPATITIS B VACCINATION AMONG LIVER TRANSPLANT PATIENTS: A SYSTEMATIC REVIEW

C O'Leary, S Rouhani, Z Hong, J Wu
Ottawa, Ontario

P139 HEPATITIS B IMMUNE GLOBULIN AND VACCINATION TO PREVENT TRANSMISSION OF HEPATITIS B VIRUS FROM MOTHER TO INFANT: A SYSTEMATIC REVIEW

C O'Leary, Z Hong, J Wu
Ottawa, Ontario

P140 OPTIMIZATION OF HEPATITIS B VACCINE RESPONSES IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

D Salloum, S McNeil, S Soroka
Ottawa, Ontario

P141 REACTOGENICITY OF REPEATED SEASONAL INFLUENZA VACCINE DELIVERED BY INTRADERMAL MICROINJECTION: RESULTS FROM A RANDOMISED CONTROLLED OPEN LABEL TRIAL IN ADULTS

M Saville, I Leroux-Roels, G Leroux-Roels, M De Decker, I Meyer, M Seiberling, L Barreto
France

P142 INTRADERMAL INFLUENZA VACCINE ELICITS SUPERIOR IMMUNE RESPONSES IN ADULTS AGED ≥60 YEARS: A RANDOMIZED CONTROLLED PHASE 3 TRIAL

M Saville, R Arnou, G Icardi, M De Decker, A Ambrozaitis, L Barreto
France

P143 HIGH RISK OF ANAL CANCER IN INDIVIDUAL TREATED FOR ANAL CONDYLOMAS IN Québec PROVINCE (1990-1999)

M Steben, R Louchini, E Duarte-Franco, P Goggin
Montréal, Québec

P144 A TRAVEL-RELATED POSSIBLE CASE OF VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS (VAPP)

T Diener, S Desai, NJ Lowry, C Talukdar, W Chrusch, BJK Tan
Regina, Saskatchewan



MONDAY, DECEMBER 1

06:30 – 08:30

Advances in Influenza Vaccination

Dominion Ballroom

This session has been co-developed by the Canadian Paediatric Society and sanofi pasteur.

Faculty

Reviewer: Dr. Clementine Tang

Chair: Dr. Jeffrey Scott

Presenters: Dr. Allison McGeer, Dr. Arnold Monto, Dr. Fred Ruben

Target audience

Paediatricians

Paediatric Infectious Disease Specialists

Infectious Disease Specialists

Vaccinologists

Family Physicians

Public Health Nurses

Medical Officers of Health

Community Medicine Specialists

Overview

An informative and interactive program focussing on the latest developments in influenza vaccination. Internationally recognized experts in the fields of epidemiology, microbiology and infectious disease will address the morbidity and mortality associated with influenza and will propose the need for new influenza vaccines. Particular attention will be given to exploring the measurement of vaccine protection and evaluating new innovations in influenza vaccination technology

Objectives

At the end of this symposium, health care providers will be able to:

- Distinguish the importance of influenza vaccination;
- Measure the effectiveness of influenza vaccination; and
- Explore the progress of new innovations in the area of influenza vaccination



Program

- 06:30 Breakfast
- 07:00 Welcome and opening remarks
 Dr. Jeffrey Scott
- 07:05 Need for an improved influenza vaccine
Objectives:
- Determine the impact of influenza disease in terms of morbidity and mortality
 - Understand immunosenescence and the effectiveness of current influenza vaccines in the elderly
- Dr. Allison McGeer
- 07:20 Q&A/ARS
- 07:25 Measurement of protection: How do we determine how well the vaccine works?
Objectives:
- Investigate the relationship between clinical trial results and the effectiveness of influenza vaccination
 - Identify future areas of research in the true evaluation of population effectiveness of influenza vaccines
- Dr. Arnold Monto
- 07:40 Q&A/ARS
- 07:45 New technology in influenza vaccination
Objectives:
 Evaluate the applications and target populations for:
- Nasal vaccines
 - Adjuvanted vaccines
 - Increased dose vaccines
 - Intra-dermal administration vaccination
- Dr. Fred Ruben
- 08:15 Q&A/ARS
- 08:25 Summary remarks and evaluation
 Dr. Jeffrey Scott
- 08:30 Adjournment





07:00 – 08:30

A Pneumococcal Vaccine Program Report Card: “A” Student or Summer School Attendee?

Civic Ballroom

This session has been co-developed by Canadian Paediatric Society and Wyeth.

Participants in this program will:

- Gain insight into the changing epidemiology of pneumococcal disease in children and adults;
- Understand the current burden of pneumococcal disease in Canada and the potential for reducing the burden with vaccine programs; and
- Review the success of Canadian pneumococcal vaccine programs.

Program

07:00 Presentations
Meeting Chair: Dr. Brian Ward

Serotype Evolution and the Future of Pneumococcal Conjugate Vaccines
Dr. Jim Kellner

Review the Changes in the Canadian Landscape in Infants
Dr. Jim Kellner

Can Our Immunization Program be Improved?
What have we Learned?
Dr. Allison McGeer

Review the Changes in the Canadian Landscape in Adults
Dr. Allison McGeer

08:05 Expert Q & A



TUESDAY, DECEMBER 2

07:00 – 08:30

Update on the control of Invasive Meningococcal Disease in Canada and the use of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Against Serogroups A, C, Y, and W-135

Dominion Ballroom

This session has been co-developed by the Canadian Paediatric Society and sanofi pasteur.

Faculty

Reviewer: Dr. Francois Boucher
Chair: Dr. Robert Bortolussi
Presenters: Dr. Julie Bettinger, Dr. Scott Halperin

Target audience

Paediatricians
Paediatric Infectious Disease Specialists
Infectious Disease Specialists
Vaccinologists
Family Physicians
Public Health Nurses
Medical Officers of Health
Community Medicine Specialists

Overview

The program will focus on an update on the burden of Invasive Meningococcal Disease (IMD) in Canada and prevention with a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Against Serogroups A, C, Y, and W-135

Objectives

At the end of this symposium participants will be able to:

- Evaluate the prevention and management of invasive meningococcal disease in Canada today
- Investigate the use of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W-135



Program

06:30 Breakfast

07:00 Welcome and opening remarks
Dr. Robert Bortolussi

07:05 The burden of IMD in Canada
At the end of this presentation, participants will be able to:

- Assess the impact of invasive meningococcal disease and immunization programs in Canada
- Summarize the IMPACT data from a national and provincial perspective
- Evaluate the effectiveness of current meningococcal surveillance methods
- Analyze age and serogroup distribution in Canada

Dr. Julie Bettinger

07:35 Q&A/ARS

07:45 IMD prevention: Quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W-135
At the end of this presentation, participants will be able to:

- Differentiate the attributes of the quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine from other available vaccines
- Interpret the guidelines for the appropriate use of quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine
- Assess future applications of quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine

Dr. Scott Halperin

08:15 Q&A/ARS

08:25 Summary remarks and evaluation
Dr. Robert Bortolussi

08:30 Adjournment



06:30 – 08:30

**Zoster and Post-Herpetic Neuralgia: Is this a Disease Worth Preventing?
A Burning Question.**

Civic Ballroom

This session has been co-developed by the Canadian Paediatric Society and Merck Frosst Canada.

Faculty:

Chair: Dr. Vivien Brown

Presenters: Dr. C Peter N Watson, Dr. Caroline Quach

Target audience

Paediatricians

Paediatric Infectious Disease Specialists

Infectious Disease Specialists

Family Physicians

Public Health Nurses

Medical Officers of Health

Community Medicine specialists

Overview

An informative and interactive program focused on providing the health care professionals with knowledge of Herpes zoster (HZ), its clinical manifestations, epidemiology, and the burden of illness Post Herpetic Neuralgia (PHN). This symposium will also examine a new approach of utilizing a live attenuated zoster vaccine as a safe and effective option in preventing HZ and PHN.

Objectives

At the end of this symposium, health care providers will be able to:

- Describe the pathophysiology and clinical presentation of herpes zoster (HZ) and post-herpetic neuralgia (PHN);
- Recognize the epidemiology and burden of HZ and PHN;
- Discuss best practices and limitations for acute zoster pain management and PHN treatment; and
- Assess the recent data and potential benefits of immunization to prevent HZ and PHN.



Program

06:30 Breakfast

07:00 Introduction and Pre-Test
Dr. Vivien Brown

07:10 Clinical Burden of herpes zoster and post-herpetic neuralgia

Objectives:

- Describe the pathophysiology and clinical presentation of herpes zoster (HZ) and post-herpetic neuralgia (PHN)
- Recognize the epidemiology and burden of HZ and PHN

Dr. C Peter N Watson

07:35 Q&A/ARS

07:45 Immunization to prevent HZ and PHN

Objectives:

- Discuss best practices and limitations for acute zoster pain management and PHN treatment
 - Assess the recent data and potential benefits of immunization to prevent HZ and PHN
- Dr. Caroline Quach

08:10 Q&A/ARS

08:25 Conclusion and post-test and evaluation
Dr. Vivien Brown

08:30 Adjournment



WEDNESDAY, DECEMBER 3

07:00 – 08:30

Advances in Protection Against Pneumococcal Disease

Civic Ballroom

This session has been co-developed by Canadian Paediatric Society and GlaxoSmithKline.

Participants in this program will:

- Be provided with new scientific information on trends in pneumococcal disease;
- Be able to describe pneumococcal and non-typable H. influenzae (NTHi) data as it pertains to AOM; and
- Be able to discuss the clinical impact of pneumococcal disease beyond IPD.

Program

- 07:00 Introductions, Review of Objectives & Agenda
Bruce Tapiero
- 07:10 The Changing Landscape of IPD: What's New
Steven Black
- 07:35 Reducing the Burden of AOM in Children: Current and Future Vaccine Strategies
Stephen Pelton
- 08:00 Panel Discussion and Q & A
- 08:25 Closing Remarks & Evaluation
Bruce Tapiero



Program Committee

Dr. Arlene King, Co-Chair

Director General

Centre for Immunization and Respiratory Infectious Diseases

Public Health Agency of Canada

Dr. Margaret L. Russell, Co-Chair

Canadian Association for Immunization Research and Evaluation

Ms. Angela Slobodian, Canadian Coalition for Immunization Awareness and Promotion

Dr. Susan Bowles, Canadian Pharmacists Association

Ms. Gordean Bjornson, Canadian Association for Immunization Research and Evaluation

Dr. Gaston De Serres, Institut national de santé publique du Québec

Ms. Gina Dumaresq, First Nations and Inuit Branch, Health Canada

Dr. Ian Gemmill, Kingston, Frontenac and Lennox & Addington Public Health

Ms. Alexandra Henteleff, Manitoba Public Health

Dr. Bonnie Henry, National Specialty Society of Community Medicine

Dr. Barbara Kawa, Ontario Ministry of Health and Long Term Care

Dr. Joanne Langley, National Advisory Committee on Immunization

Dr. Barbara Law, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Ms. Michelle M. Long, Manitoba Health & Healthy Living

Dr. Shelly McNeil, Association of Medical Microbiology and Infectious Disease Canada

Ms. Tamsin Morgana, Vancouver Coastal Health

Dr. Harold Rode, Pandemic Flu Division, Biologics and Genetic Therapies Directorate, Health Canada

Dr. Bhagirath Singh, Canadian Institutes for Health Research

Ms. Jill Skinner, Canadian Medical Association

Ms. Rosalie Tuchscherer, Saskatchewan Ministry of Health



Operations Committee

Ms. Mahnaz FarhangMehar, Co-chair
*Interim Director, Immunization Programs
Centre for Immunization and Respiratory Infectious Diseases
Public Health Agency of Canada*

Ms. Debra Lynkowski, Co-chair
*Chief Executive Officer
Canadian Public Health Association*

Ms. Gordean Bjornson, Canadian Association for Immunization Research and Evaluation

Ms. Marie Adèle Davis, Canadian Paediatric Society

Ms. Michelle M. Long, Manitoba Health & Healthy Living

Ms. Tamsin Morgana, Vancouver Coastal Health

Dr. Philip Schwab, BIOTECCanada

Dr. Barbara Yaffe, Toronto Public Health

Abstract Review and Adjudication Committee

Dr. Margaret L. Russell, Canadian Association for Immunization Research and Evaluation

Ms. Gordean Bjornson, Canadian Association for Immunization Research and Evaluation

Session Review and Conference Evaluation Committee

Ms. Lyne Cantin, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Ms. Mahnaz FarhangMehar, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Ms. Beth Halperin, Dalhousie University

Ms. Alexandra Henteleff, Manitoba Health

Dr. Shelly McNeil, Association for Medical Microbiology and Infectious Diseases Canada

Dr. Susan Tallett, Hospital for Sick Children



CONFERENCE ORGANIZING COMMITTEES



Travel Bursary Review Committee

Ms. Michelle Long, Manitoba Health & Healthy Living

Ms. Tamsin Morgana, Vancouver Coastal Health

Ms. Beverley Webster, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Conference Coordination Team

This coordination team is composed of the Public Health Agency of Canada project team and event management company. The Conference Coordination team includes:

Ms. Lyne Cantin, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Ms. Beverley Webster, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Conference Secretariat

Conference Secretariat

275 Bay Street

Ottawa ON K1R 5Z5

Telephone: (613) 238-4870

Facsimile: (613) 236-2727

E-mail: immunconf@phac-aspc.gc.ca



Track your learning!

Check off the Learning Domains that are covered by the Conference sessions you attend.

The Immunization Competencies for Health Professionals are noted beside each session description in the Final Program.

Learning Domain for each of the Immunization Competencies for Health Professionals
 Domaine d'apprentissage de chacune des compétences en immunisation des professionnels de la santé

SESSIONS SÉANCES	The Immune System and Vaccines Système immunitaire et vaccins	Vaccine Preventable Diseases Maladies pouvant être prévenues par des vaccins	Vaccine Development & Evaluation Élaboration et évaluation de vaccins	The Type of Immunizing Agents Types d'agents immunisants	Population Health Santé des populations	Communication	Storage and Handling of Immunization Agents Entreposage et manipulation des agents d'immunisation
	IC1 / CI1	IC2 / CI2	IC3 / CI3	IC4 / CI4	IC5 / CI5	IC6 / CI6	IC7 / CI7
	Explains how vaccine works using basic knowledge of immune system Expliquer comment les vaccins fonctionnent en démontrant une connaissance fondamentale du système immunitaire	Demonstrates an understanding of the rationale & benefit of immunization Démontrer une compréhension de la raison d'être et des avantages du recours à l'immunisation	Integrates into practice knowledge about the main steps in vaccine development and evaluation Intégrer dans la pratique les connaissances concernant les étapes principales de l'élaboration et de l'évaluation des vaccins	Applies the knowledge of the components and properties of immunizing agents as needed for safe and effective practice Appliquer les connaissances relatives aux composants et aux propriétés des agents immunisants nécessaires à une pratique efficace et sécuritaire	Applies relevant principles of population health for improving immunization rates Appliquer des principes pertinents de santé des populations afin d'améliorer les taux de vaccination	Communicates effectively about immunization as relevant to the practice setting(s) Communiquer efficacement en matière d'immunisation, selon le contexte de pratique	Implements Canadian guidelines when storing, handling or transporting vaccines Appliquer les lignes directrices canadiennes relatives à l'entreposage, à la manipulation et au transport des vaccins
Plenary I Plénière I							
Concurrent Session Séance simultanée							
Plenary II Plénière II							
Plenary III Plénière III							
Concurrent Session Séance simultanée							
Concurrent Session Séance simultanée							
Plenary IV Plénière IV							
Plenary V Plénière V							
Concurrent Session Séance simultanée							
Concurrent Session Séance simultanée							
Plenary VI Plénière VI							
Plenary VII Plénière VII							
Lunchtime Workshop Atelier du dîner							
Lunchtime Workshop Atelier du dîner							

Fill in the title of each session / Inscrivez le titre de chacune des séances